lung-cancer-treatment

肺がん治療 MOC

肺がん (NSCLC・SCLC・NEC) および胸部悪性腫瘍 (胸腺腫・中皮腫) の治療研究を統合する。Driver 別の標的治療、免疫療法、化学療法、放射線併用、周術期療法、supportive care、irAE 管理を含む。手術 / 放射線療法単独研究は含まないが、薬物療法との集学的治療として登場するものは対象。

ドメイン定義

含む: NSCLC (EGFR / ALK / ROS1 / HER2 / Driver-Other / Driver negative)、SCLC、NEC、胸腺上皮性腫瘍、悪性中皮腫の薬物療法臨床研究。oncogene-matched な標的治療 (1L 選択的 TKI、耐性後 ADC / 二重特異性抗体 / 次世代 TKI、術後補助標的療法、KRAS G12D 分解剤等の新規標的)、免疫療法 (ICI 単剤 / 化学療法併用 / dual IO / 周術期 IO)、化学療法・抗血管新生療法、DLL3 BiTE などの新規モダリティ。Supportive care、irAE 管理。

含まない: 手術・放射線療法単独研究 (集学的治療の一部として薬物療法と併記される場合は対象)、肺がん非腫瘍領域の呼吸器疾患 (→ respiratory-diseases)、driver 機序・耐性生物学そのものの基礎研究 (→ lung-cancer-biology)。

現状の合意 (State of the Field)

Driver 陽性 NSCLC の 1 次治療標準：EGFR 変異陽性では FLAURA Soria et al. NEnglJMed 2018 で osimertinib が gefitinib/erlotinib に対し mPFS 18.9 vs 10.2 か月 (HR 0.46)・新規 CNS 病変 6% vs 15% を示し 3rd-gen TKI 1L 標準を確立、final OS も 38.6 vs 31.8 か月で延長した。治療強化として FLAURA2 では Osimertinib + Platinum/Pemetrexed が単剤に PFS HR 0.62 (29.4 vs 19.9 か月) で優越し、最終解析で OS も 47.5 vs 36.7 か月 (HR 0.77) と有意延長が確定した (Zhao et al. NatRevClinOncol 2026)。並行して MARIPOSA (Cho et al. NEnglJMed 2024) で Amivantamab (EGFR×MET 二重特異性抗体) + Lazertinib が単剤に PFS (progression-free survival) HR 0.70 (23.7 vs 16.6 か月)・OS (overall survival) HR 0.75 で優越し、「TKI (tyrosine kinase inhibitor) 単剤 (FLAURA) vs TKI+化学療法 (FLAURA2) vs TKI+二重特異性抗体 (MARIPOSA)」の 3 択 1L (first-line) 戦略時代となった。いずれも DTP (drug-tolerant persister) 細胞・早期耐性クローンを upfront で削ぐことで耐性出現を遅延させる戦略であり、高リスク (L858R / TP53・RB1 co-mutation / 脳転移 / high tumor burden) での add-on 選択と、強化で増える「未知の耐性表現型」の制御が central question である (Zhao et al. NatRevClinOncol 2026)。

Osimertinib 耐性後の ADC (antibody-drug conjugate)・二重特異性抗体シーケンス：1L osimertinib 耐性は C797S (約 6%)・MET 増幅 (15% 超)・SCLC 転換 (3-10%、RB1/TP53 共欠失で転換リスク約 40 倍) など多層的で、約半数は既知の単一遺伝子異常で説明できず、ctDNA 動態による「分子生物学的耐性」の早期検出と適応的介入へのパラダイムシフトが進む (Zhao et al. NatRevClinOncol 2026)。耐性機序別の biomarker (生体指標) 誘導戦略として、MET 増幅例では savolitinib + osimertinib が化学療法に PFS HR 0.32 (SACHI 第 III 相、3rd-gen 既治療サブ群 6.9 vs 3.0 か月) で優越し、MET ADC では telisotuzumab vedotin が ORR (objective response rate) 50%、TOPO1 (topoisomerase I、トポイソメラーゼ I) payload の新規 MET ADC telisotuzumab adizutecan が MET 発現非依存に ORR 63.4%・mPFS 10.9 か月、HER2 共発現への T-DXd (trastuzumab deruxtecan) は DESTINY-Lung03 で ORR 68.4% を示した (Zhao et al. NatRevClinOncol 2026)。biomarker 非選択の ADC では TROP2 標的 Dato-DXd (datopotamab deruxtecan; ORR 43%・OS 15.6 か月)・sac-TMT (sacituzumab tirumotecan; OptiTROP-Lung04 で PFS 8.3 vs 4.3 か月、HR 0.49)、HER3 標的 patritumab deruxtecan (HERTHENA-Lung01 ORR 29.8%・OS 11.9 か月) が確立しつつあり、PD-1×VEGF 二重特異性抗体の ivonescimab + 化学療法も EGFR-TKI 既治療で PFS HR 0.46 (HARMONi-A、7.1 vs 4.8 か月) を示した (Zhao et al. NatRevClinOncol 2026)。これにより osimertinib 耐性後は「組織 / 液体生検で耐性機序を同定 → MET/HER2 標的または非選択 ADC を sequencing」というアルゴリズムが具体化し、4th-gen EGFR-TKI による C797S 共変異克服と組み合わせる段階に入った。

希少 driver の標的治療と耐性後シーケンス：ALK 陽性では CROWN Shaw et al. NEnglJMed 2020 で lorlatinib が crizotinib に PFS HR 0.28・頭蓋内 CR (complete response、完全奏効) 71% を示し、5 年解析でも mPFS 未到達・5 年 PFS 60% (Solomon et al. JClinOncol 2024) と固形腫瘍で最長の単剤 PFS を記録。ROS1 では TRIDENT-1 Drilon et al. NEnglJMed 2024 で repotrectinib が TKI-naive ORR 79%・mPFS 35.7 か月・G2032R 耐性 ORR 59% を示し標準を更新、さらに TRK 温存設計 (シアノ基で TRKA Tyr591 と立体衝突) で CNS 毒性を抑えた次世代 brain-penetrant 阻害薬 JYP0322 が TKI-naive ORR 95.7%・G2032R ORR 78%・頭蓋内 ORR 56%、めまい 6.7% と既存 2nd-gen の CNS 毒性 30-50% を大幅に下回る忍容性を報告した (Ma et al. CancerCell 2026)。RET では LIBRETTO-431 Zhou et al. NEnglJMed 2023 で selpercatinib 1L が IO+chemo に PFS HR 0.46 で勝利し、術後補助でも LIBRETTO-432 で stage IB-IIIA に 2 年 EFS (event-free survival、無イベント生存) 92% vs 61% (HR 0.17) と ADAURA・ALINA に匹敵する効果量で再発リスクを 83% 低減した (Wu et al. NEnglJMed 2026)。HER2 変異では DESTINY-Lung02 Goto et al. JClinOncol 2023 で T-DXd 5.4 mg/kg が ORR 49%・ILD 13% と 6.4 mg/kg より良好な安全性で最適用量を確立し、DESTINY-Lung04 (1L T-DXd vs platinum+pembrolizumab) の readout が 1L 標準を確定する見込みである。KRAS では G12C 阻害薬 sotorasib / adagrasib / divarasib に加え、システイン残基を欠き従来 undruggable とされた G12D を標的とする first-in-class 分解剤 setidegrasib (VHL E3 リガーゼ動員型 PROTAC (proteolysis-targeting chimera、標的タンパク質分解誘導キメラ)) が NSCLC で PR (partial response、部分奏効) 36%・mPFS 8.3 か月、PDAC (pancreatic ductal adenocarcinoma、膵管腺癌) でも OS 10.3 か月を示し (Park et al. NEnglJMed 2026)、標的が pan-RAS / G12D へ拡張しつつある。総じて driver 陽性肺がんは「mutation-matched 1L selective TKI → 耐性機構別の ADC / bispecific / 次世代 TKI」のアルゴリズムが標準化され、術後補助でも ADAURA の Osimertinib (DFS (disease-free survival、無病生存) HR 0.20 / OS HR 0.49) を起点に EGFR・ALK・RET へ oncogene-matched adjuvant が広がった。

Driver 陰性 NSCLC における免疫療法の階層化：PD-L1 TPS (tumor proportion score) ≥50% では KEYNOTE-024 Reck et al. NEnglJMed 2016 が pembrolizumab 単剤の優越性 (OS HR 0.60) を確立し、PD-L1 低発現〜陰性では KEYNOTE-189 Gandhi et al. NEnglJMed 2018 の IO (immuno-oncology) + 化学療法が OS HR 0.49 で PD-L1 全層 benefit を確認した。HARMONi-2 (Zhou 2024) では PD-1×VEGF 二重特異性抗体の Ivonescimab 単剤が PD-L1+ NSCLC 1L で pembrolizumab 単剤に PFS HR 0.51 で優越を示し、IO 1L の標準を二重特異性抗体が塗り替える可能性が浮上した (国際第 III 相進行中)。切除不能 Stage III では PACIFIC の CRT (chemoradiotherapy、化学放射線療法) 後 durvalumab が OS HR 0.68 で標準。周術期 IO が新たな標準として確立: KEYNOTE-671 Wakelee et al. NEnglJMed 2023 で 周術期 pembrolizumab + 化学療法が EFS (event-free survival) HR 0.58・MPR (major pathological response) 30.2% vs 11.0%・pCR (pathological complete response) 18.1% vs 4.0% を示し、AEGEAN Heymach et al. NEnglJMed 2023 で 周術期 durvalumab + 化学療法が EFS HR 0.68・pCR 17.2% vs 4.3% を達成。CheckMate-816 の術前 Nivo + 化学療法 (pCR 24%) と合わせ、Stage II–IIIB 切除可能 NSCLC に対する周術期 IO + 化学療法は class effect (クラス効果) として確認された。一方 STK11/KEAP1 共変異 (KL group) は IO primary resistance を示す層として再認識され、glutaminase 阻害・radiotherapy 併用・metabolic vulnerability 標的化の臨床試験が進行する。

SCLC・NEC・希少胸部腫瘍：SCLC では IMpower133 / CASPIAN で IO 化療併用が 1L 標準となったが OS 改善は中央値 2–3 か月で「IO の SCLC への効果は限定的」と認識されている。転機となったのが DLL3×CD3 BiTE (bispecific T-cell engager、二重特異性 T 細胞誘導抗体) の Tarlatamab で、第 II 相 DeLLphi-301 で 既治療 SCLC に ORR 40% を示した後、第 III 相 DeLLphi-304 (n=509) でプラチナ既治療 2L において標準化学療法 (topotecan / lurbinectedin / amrubicin) に OS 13.6 vs 8.3 か月 (HR 0.60)・ORR 35% vs 20%・Grade ≥3 AE 54% vs 80% で優越し、プラチナ抵抗性サブ群でも OS HR 0.62 と一貫、CRS (cytokine release syndrome、サイトカイン放出症候群) の大半が Grade 1-2 で外来 step-up dosing 管理が確立した (Mountzios et al. NEnglJMed 2025)。維持療法でも lurbinectedin + atezolizumab が atezolizumab 単独に PFS 5.4 vs 2.1 か月 (HR 0.54)・OS 13.2 vs 10.6 か月 (HR 0.73) で優越し (IMforte 第 III 相、Paz-Ares et al. Lancet 2025)、CheckMate 451 / MERU など過去の維持強化が陰性だった中で初めて両主要評価項目を満たした。DeLLphi-305 (1L 維持) / DeLLphi-306 (LS-SCLC 維持) と合わせ、SCLC は IO+化療 plateau 後の DLL3 BiTE / cfDNA (cell-free DNA、無細胞 DNA) methylome subtype-driven sequencing 時代へ移行しつつある。胸腺腫・胸腺がんは ITMIG (International Thymic Malignancy Interest Group) / NCCN (National Comprehensive Cancer Network) ガイドライン中心、悪性中皮腫では nivolumab + ipilimumab dual IO (CheckMate-743) が pemetrexed + cisplatin に対し OS 優越を示し、TROP2 ADC の胸腺上皮腫瘍展開も検討段階。

Supportive / irAE (immune-related adverse events、免疫関連有害事象)：化学療法・分子標的薬・ICI (immune checkpoint inhibitor、免疫チェックポイント阻害薬) 共通の FN (febrile neutropenia、発熱性好中球減少症) 予防・制吐・骨髄抑制管理に加え、ICI 特有の irAE (pneumonitis・colitis・thyroiditis・myocarditis・hypophysitis) の早期検出と steroid / 免疫抑制管理が標準化された。ADC class effect の ILD (interstitial lung disease、間質性肺疾患) (deruxtecan 系列の 5-13%, fatal 約1%) が新たな major toxicity として認識され、既存肺疾患 / アジア人種 / 肺転移を危険因子とする早期 CT 検出 + steroid 介入プロトコルが確立しつつある。CAR-T (chimeric antigen receptor T-cell、キメラ抗原受容体 T 細胞) 系では CRS / ICANS (immune effector cell-associated neurotoxicity syndrome) の Lee criteria + tocilizumab 早期介入が血液腫瘍領域で確立し、固形腫瘍 BiTE (Tarlatamab) でも step-up dosing で外来管理可能となった。

主要エンティティ

薬剤クラス (17 classes — Phase B Top 20 拡張)

Driver targeted (6):

• EGFR-TKI — Gefitinib / Erlotinib / Afatinib / Osimertinib / Lazertinib 等の世代展開
• ALK-TKI — Crizotinib / Alectinib / Brigatinib / Lorlatinib 等の世代展開
• ROS1-TKI — Crizotinib / Entrectinib / Repotrectinib / Lorlatinib (ALK と kinase 77% 同一)
• RET-inhibitor — Selpercatinib / Pralsetinib (LIBRETTO-431 で IO+chemo 撃破)
• KRAS-G12C-inhibitor — Sotorasib / Adagrasib / Divarasib
• NTRK-inhibitor — Larotrectinib / Entrectinib / Repotrectinib (tissue-agnostic paradigm)

Immunotherapy (3):

• PD-1-inhibitor — Pembrolizumab / Nivolumab 等 8 members
• PD-L1-inhibitor — Atezolizumab / Durvalumab / Avelumab / Sugemalimab
• CTLA-4-inhibitor — Ipilimumab / Tremelimumab (dual IO partner)

Novel modalities (2):

• ADC — T-DXd / Dato-DXd / HER3-DXd / Telisotuzumab vedotin (payload diversity)
• BiTE-bispecific — Tarlatamab (DLL3) / Amivantamab (EGFR×MET) / Ivonescimab (PD-1×VEGF)

Antibody / chemo / DDR backbone (6):

• anti-VEGF-antibody — Bevacizumab / Ramucirumab (IMpower150 / RELAY backbone)
• anti-EGFR-antibody — Cetuximab / Necitumumab (historical, 現代 niche)
• Platinum-chemotherapy — Cisplatin / Carboplatin (IO+chemo の foundation)
• Pemetrexed — 非扁平 NSCLC + mesothelioma backbone (histology-specific paradigm)
• Taxane — Paclitaxel / nab-paclitaxel / Docetaxel (KEYNOTE-407 backbone, 2L 単剤)
• PARP-inhibitor — Olaparib / Niraparib (NSCLC niche、SCLC SLFN11+ で開発)

(Phase B 拡張候補: MET 個別 inhibitor / TIGIT inhibitor / LAG-3 inhibitor / 4th-gen ALK 等)

遺伝子 (治療標的 / biomarker、詳細は lung-cancer-biology)

• Major drivers: EGFR / ALK / KRAS / ROS1 / HER2 / MET / BRAF / RET / NTRK
• IO biomarker / co-mutation: PD-L1 / TP53 / STK11 / KEAP1
• SCLC subtype (治療応答性に関連) : ASCL1 / MYC (→ DLL3 / Aurora kinase 標的化), RB1 (dual loss baseline)

試験 (20 trials — Phase B Top 20 拡張)

EGFR-targeted (5):

• FLAURA — 1L EGFR+ Osimertinib (PFS HR 0.46 / OS HR 0.799)
• FLAURA2 — 1L EGFR+ Osimertinib+chemo vs Osimertinib (PFS HR 0.62 / CNS PFS HR 0.47)
• AURA3 — 2L T790M+ Osimertinib (PFS HR 0.30)
• ADAURA — Adjuvant Osimertinib (DFS HR 0.20 / OS HR 0.49)
• IPASS — 1L Gefitinib EGFR+ paradigm 起点 (PFS HR 0.48 EGFR+)

ALK-targeted (4):

• ALEX — 1L ALK+ Alectinib (PFS HR 0.47 / 5-yr OS 62.5%)
• CROWN — 1L ALK+ Lorlatinib (5-yr PFS 60%)
• ALTA-1L — 1L ALK+ Brigatinib (PFS HR 0.49)
• PROFILE-1014 — 1L ALK+ Crizotinib paradigm 起点 (PFS HR 0.45)

IO 1L NSCLC (6):

• KEYNOTE-024 — 1L PD-L1 ≥50% Pembrolizumab 単剤 (OS HR 0.60)
• KEYNOTE-189 — 1L 非扁平 IO+chemo (OS HR 0.49)
• KEYNOTE-407 — 1L 扁平 IO+chemo (OS HR 0.64)
• CheckMate-227 — 1L dual IO chemo-free (OS HR 0.79 PD-L1 ≥1%)
• CheckMate-9LA — 1L dual IO + 限定 2 cycles chemo (OS HR 0.66)
• IMpower150 — 1L 非扁平 ABCP (atezo+bev+chemo, EGFR+ subset 含む, OS HR 0.78)

Stage III / 周術期 (3):

• PACIFIC — Stage III 化療放射線後 Durvalumab consolidation (PFS HR 0.51)
• CheckMate-816 — 術前 Nivolumab+chemo (pCR 24% vs 2.2% / EFS HR 0.63)
• KEYNOTE-671 — Perioperative Pembrolizumab+chemo (EFS HR 0.58 / OS HR 0.72)

SCLC paradigm (3):

• IMpower133 — 1L ES-SCLC Atezo+chemo (OS HR 0.70、SCLC IO 化療 30+ 年ぶり改革)
• CASPIAN — 1L ES-SCLC Durvalumab+chemo (OS HR 0.73、Tremelimumab 追加陰性)
• DeLLphi-301 — Tarlatamab (DLL3 BiTE) 既治療 SCLC (ORR 40% / mOS 14.3 mo、SCLC paradigm shift)

主要概念

• EGFR-T790M-resistance — 1st/2nd-gen EGFR-TKI 耐性 paradigm
• EGFR-C797S-resistance — 3rd-gen Osimertinib 後耐性、cis/trans allele、4th-gen 開発
• ALK-G1202R-compound-mutations — Lorlatinib 後 compound mutation、4th-gen 設計
• KRAS-co-mutation-landscape — KP / KL / KC 三亜型と STK11/KEAP1 IO 抵抗性
• Lineage-plasticity — SCLC transformation / HPCS lineage hub
• Perioperative-IO — KEYNOTE-671 / AEGEAN / CheckMate-816 による周術期 IO class effect 確立
• ADC-resistance-mechanisms — antigen loss / payload efflux / internalization 障害の多層構造
• irAE-pathophysiology — IO 治療下 immune-related adverse events の機序と管理
• Cancer-dormancy — adjuvant / MRD context, awakening prevention strategy
• IO-primary-resistance — STK11/KEAP1 loss、immune-excluded TME、MHC-I loss
• Tumor-angiogenesis — anti-VEGF + IO の vessel normalization 根拠

Open Questions

• EGFR 1L 強化の患者選択：FLAURA2 (TKI+chemo) vs MARIPOSA (TKI+bispecific) vs FLAURA (TKI 単剤) の 3 択を L858R・TP53/RB1 co-mutation・脳転移・腫瘍量・毒性許容度でどう層別化するか、upfront 強化後の OS gain と引き換えに増える「未知の耐性表現型」(既知単一遺伝子で説明できない約半数) をどう制御するか
• 耐性後 ADC シーケンスの最適化：osimertinib 耐性後の MET/HER2 標的 ADC (telisotuzumab vedotin / adizutecan / T-DXd) と TROP2 (Dato-DXd / sac-TMT)・HER3 (patritumab deruxtecan) 非選択 ADC・ivonescimab の投与順序と biomarker、ADC 間 cross-resistance と deruxtecan 系 ILD の管理、4th-gen EGFR-TKI との組合せ
• 標的補助療法は治癒か遅延か：ADAURA / LIBRETTO-432 / ALINA の補助標的療法が再発を治癒するのか遅延に留まるのか (RET 補助は OS データ未成熟)、最適投与期間、ctDNA (circulating tumor DNA) -MRD (minimal residual disease、微小残存病変) ガイドによる個別化
• SCLC DLL3 治療の位置づけ：tarlatamab を 1L 維持 (DeLLphi-305) / LS-SCLC (DeLLphi-306) へ前倒しする意義と IMforte (lurbinectedin 維持) との棲み分け、DLL3 発現・cfDNA methylome subtype による responder 選別、CRS / ICANS の外来管理標準化
• KRAS 標的の拡張：first-in-class G12D 分解剤 (setidegrasib) ・pan-RAS 阻害薬の単剤・併用での臨床的位置づけと耐性機構、STK11 / KEAP1 co-mutation による IO・標的療法抵抗性の克服
• PD-L1 を超える IO biomarker：TMB (tumor mutational burden、腫瘍遺伝子変異量)・HLA・MHC-II・TIL (tumor-infiltrating lymphocyte、腫瘍浸潤リンパ球)・腸内細菌叢の実装、PD-1×VEGF 二重特異性抗体 (ivonescimab) が IO 1L 標準を塗り替えるか、irAE 発症予測

重要論文 Top 10

1. ★★★★★ Gandhi et al. NEnglJMed 2018 — KEYNOTE-189: 非扁平 1L IO+chemo で OS HR 0.49、PD-L1 全層で benefit
2. ★★★★★ Soria et al. NEnglJMed 2018 — FLAURA: EGFR+ 1L Osimertinib で mPFS 18.9 vs 10.2 mo (HR 0.46), 3rd-gen TKI 標準化
3. ★★★★★ Antonia et al. NEnglJMed 2017 — PACIFIC: Stage III CRT 後 Durvalumab consolidation で OS HR 0.68
4. ★★★★★ Peters et al. NEnglJMed 2017 — ALEX: 1L ALK+ Alectinib で PFS HR 0.47, CNS 進行 HR 0.16
5. ★★★★★ Reck et al. NEnglJMed 2016 — KEYNOTE-024: PD-L1 TPS≥50% で Pembro 単剤 OS HR 0.60
6. ★★★★★ Wu et al. NEnglJMed 2020 — ADAURA: 切除後 EGFR+ adjuvant Osimertinib 3 年, DFS HR 0.20 / OS HR 0.49
7. ★★★★★ Forde et al. NEnglJMed 2022 — CheckMate-816: 術前 Nivo+chemo, pCR 24% vs 2.2%, EFS HR 0.63
8. ★★★★★ Shaw et al. NEnglJMed 2020 — CROWN: 1L Lorlatinib, 5-yr PFS 60%, intracranial PFS 96% at 12mo
9. ★★★★★ Mok et al. NEnglJMed 2009 — IPASS: EGFR mutation を predictive biomarker として確立、targeted therapy paradigm 起点
10. ★★★★ Paz-Ares et al. JThoracOncol 2020 — KEYNOTE-407: 1L 扁平 IO+chemo, OS HR 0.64, PD-L1 全層 benefit

最新追加論文 Top 10

• Okamoto et al. LungCancer 2026 — Clinical-NSCLC-EGFR
• Itchins et al. LungCancer 2026 — Clinical-NSCLC-ROS1
• Borghaei et al. ClinCancerRes 2026 — Clinical-NSCLC-Driver negative
• Zamulko et al. ClinCancerRes 2026 — Clinical-NSCLC-Driver negative
• Vujanovic et al. ClinCancerRes 2026 — Clinical-NSCLC-Driver negative
• Trotta et al. Cell 2026 — Clinical-SCLC
• Chien et al. CancerImmunolImmunother 2026 — Clinical-NSCLC-Driver negative
• Ulas et al. JImmunotherCancer 2026 — Clinical-NSCLC-Driver negative
• Zhang et al. FrontImmunol 2026 — Clinical-SCLC
• Lu et al. ClinLungCancer 2026 — Clinical-NSCLC-EGFR

全論文リスト (カテゴリ別、自動生成)

Clinical-Mesothelioma

• Lopez et al. Med 2026 — Lago-Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy strategies to restore
• Dungey et al. TrendsCancer 2026 — Mesothelioma a systemic therapy clinical trials snapshot
• Offin et al. JCancerMetastasisTreat 2023 — The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas
• Vogelzang et al. JClinOncol 2023 — Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural
• Oehl et al. ClinCancerRes 2021 — Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural
• Baas et al. Lancet 2021 — First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743) a multicentre,
• Vroman et al. JImmunotherCancer 2020 — T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in
• Blum et al. NatCommun 2019 — Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
• vanZandwijk et al. LancetOncol 2017 — Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma a
• Bueno et al. NatGenet 2016 — Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and
• Baas et al. AnnOncol 2015 — Malignant pleural mesothelioma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
• Yamada et al. CancerRes 2015 — Akt kinase-interacting protein 1 signals through CREB to drive diffuse malignant mesothelioma
• Li et al. CancerSci 2015 — Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma
• Suraokar et al. AnnOncol 2014 — Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and
• Riquelme et al. JThoracOncol 2014 — Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma
• Husain et al. ArchPatholLabMed 2013 — Guidelines for pathologic diagnosis of malignant mesothelioma 2012 update of the consensus statement from the
• Petrausch et al. BMCCancer 2012 — Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma
• Bott et al. NatGenet 2011 — The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural
• Testa et al. NatGenet 2011 — Germline BAP1 mutations predispose to malignant mesothelioma
• Zhao et al. CancerRes 2010 — Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of
• Muhsin et al. NatRevDrugDiscov 2004 — Pemetrexed disodium

Clinical-NEC

• Heijboer et al. JCOPrecisOncol 2025 — Actionable genomic alterations in large cell neuroendocrine carcinoma A european case series of patients treated with a
• Sen et al. LancetOncol 2025 — Pulmonary neuroendocrine neoplasms the molecular landscape, therapeutic challenges, and diagnosis and management
• Heijboer et al. LungCancer 2025 — Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma a nationwide registry study
• Shirai et al. LungCancer 2025 — Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung the japanese lung cancer registry
• Nassar et al. NatCommun 2025 — Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
• Fujiwara et al. AnnSurgOncol 2024 — Clinical and pathologic differences between small-cell carcinoma and large-cell neuroendocrine carcinoma of the lung
• Nicholson et al. JThoracOncol 2022 — The 2021 WHO classification of lung tumors impact of advances since 2015
• Rekhtman et al. ModPathol 2022 — Lung neuroendocrine neoplasms recent progress and persistent challenges
• Lindsay et al. BrJCancer 2021 — Large cell neuroendocrine lung carcinoma consensus statement from the british thoracic oncology group and the
• Fisch et al. FrontOncol 2021 — Comprehensive dissection of treatment patterns and outcome for patients with metastatic large-cell neuroendocrine lung
• Dudnik et al. JImmunotherCancer 2021 — Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
• Kawasaki et al. Cell 2020 — An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping
• Zhuo et al. ClinCancerRes 2020 — The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell
• Tashiro et al. IntJMolSci 2020 — Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK
• Kenmotsu et al. JClinOncol 2020 — Randomized phase III study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected
• Hermans et al. LungCancer 2020 — Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC)
• Sherman et al. LungCancer 2020 — Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
• Lantuejoul et al. TranslLungCancerRes 2020 — New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential
• Hermans et al. LungCancer 2019 — Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine car…
• Deng et al. MedSciMonit 2019 — Lung large cell neuroendocrine carcinoma an analysis of patients from the surveillance, epidemiology, and end-results
• Derks et al. ClinCancerRes 2018 — Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome
• Christopoulos et al. LungCancer 2018 — Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and
• George et al. NatCommun 2018 — Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade
• Alvarez et al. NatGenet 2018 — A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine
• Christopoulos et al. AnnOncol 2017 — Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung
• Miyoshi et al. ClinCancerRes 2017 — Genomic profiling of large-cell neuroendocrine carcinoma of the lung
• Derks et al. EurRespirJ 2017 — Chemotherapy for pulmonary large cell neuroendocrine carcinomas does the regimen matter
• Hiroshima et al. TranslLungCancerRes 2017 — Update on large cell neuroendocrine carcinoma
• Rekhtman et al. ClinCancerRes 2016 — Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and
• Naidoo et al. ClinLungCancer 2016 — LCNEC of the lung
• Derks et al. EurRespirJ 2016 — Clinical features of large cell neuroendocrine carcinoma a population-based overview
• Kunz et al. JClinOncol 2015 — Carcinoid and neuroendocrine tumors building on success
• Steuer et al. JThoracOncol 2015 — Atypical carcinoid tumor of the lung a surveillance, epidemiology, and end results database analysis
• Eba et al. JpnJClinOncol 2014 — A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for
• LeTreut et al. AnnOncol 2013 — Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma
• Niho et al. JThoracOncol 2013 — Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung a
• Chen et al. JNatlComprCancNetw 2006 — Pulmonary neuroendocrine tumors what (little) do we know
• Jones et al. Lancet 2004 — Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and
• Iyoda et al. Cancer 2001 — Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine

Clinical-NSCLC-ALK

• Mascarenhas et al. JCOGlobOncol 2026 — Current access to anaplastic lymphoma kinase testing and targeted therapies for non-small cell lung cancer in brazil
• Solomon et al. JClinOncol 2024 — Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer 5-year outcomes from the
• Felip et al. AnnOncol 2021 — Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer
• Tanimoto et al. ClinCancerRes 2021 — Proteasome inhibition overcomes ALK-TKI resistance in ALK-RearrangedTP53-mutant NSCLC via noxa expression
• Ito et al. EurJCancer 2021 — Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma
• Kim et al. FutureOncol 2021 — ALTA-2 phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed
• Camidge et al. JThoracOncol 2021 — Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC final results of phase 3 ALTA-1l trial
• Nishio et al. JThoracOncol 2021 — Brigatinib in japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase
• Naito et al. JpnJClinOncol 2021 — Brigatinib and lorlatinib their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous
• Mok et al. AnnOncol 2020 — Updated overall survival and final progression-free survival data for patients with treatment-naive advanced
• Ando et al. Cancers 2020 — Brigatinib and alectinib for ALK rearrangement positive NSCLC with or without CNS metastasis
• Dagogo-Jack et al. ClinCancerRes 2020 — MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer
• Recondo et al. ClinCancerRes 2020 — Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
• Lin et al. FutureOncol 2020 — Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the
• Camidge et al. JClinOncol 2020 — Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer second interim
• Arai et al. JThoracOncol 2020 — Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of
• Felip et al. JThoracOncol 2020 — Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small cell lung cancer results of an open-label,
• Huber et al. JThoracOncol 2020 — Brigatinib in crizotinib-refractory ALK+ NSCLC 2-year follow-up on systemic and intracranial outcomes in the phase 2
• Lin et al. JThoracOncol 2020 — Efficacy of PlatinumPemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK
• Ng et al. JThoracOncol 2020 — Early-onset pulmonary events associated with brigatinib use in advanced NSCLC
• Nishio et al. JThoracOncol 2020 — Final overall survival and other efficacy and safety results from ASCEND-3 phase II study of ceritinib in ALKi-naive
• Yang et al. LancetRespirMed 2020 — Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer
• Nakagawa et al. LungCancer 2020 — Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive
• Shaw et al. NEnglJMed 2020 — First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer
• Jahanzeb et al. Oncologist 2020 — Real-world treatment patterns and progression-free survival associated with anaplastic lymphoma kinase (ALK) tyrosine
• Kaneda et al. SciRep 2020 — Ceritinib in japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer interim analysis
• Fukuda et al. CancerRes 2019 — Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK
• Pailler et al. ClinCancerRes 2019 — Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in
• Shaw et al. JClinOncol 2019 — ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung
• Camidge et al. JThoracOncol 2019 — Management strategies for early-onset pulmonary events associated with brigatinib
• Camidge et al. JThoracOncol 2019 — Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated
• Cho et al. JThoracOncol 2019 — Efficacy and safety of ceritinib (450 mgd or 600 mgd) with food versus 750-mgd fasted in patients with ALK receptor
• Gemma et al. JThoracOncol 2019 — Interstitial lung disease onset and its risk factors in japanese patients with ALK-positive NSCLC after treatment with
• Makimoto et al. JThoracOncol 2019 — Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden
• Zhou et al. LancetRespirMed 2019 — Alectinib versus crizotinib in untreated asian patients with anaplastic lymphoma kinase-positive non-small-cell lung
• Descourt et al. LungCancer 2019 — Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors
• Trigg et al. NatCommun 2019 — The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
• Gadgeel et al. AnnOncol 2018 — Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer
• Novello et al. AnnOncol 2018 — Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung
• Soria et al. AnnOncol 2018 — Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive pat…
• Yoda et al. CancerDiscov 2018 — Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer
• Redaelli et al. CancerRes 2018 — Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer
• Hida et al. CancerSci 2018 — Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic
• Katayama et al. CancerSci 2018 — Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
• McCoach et al. ClinCancerRes 2018 — Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance
• McCoach et al. ClinCancerRes 2018 — Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer
• Cadranel et al. ERJOpenRes 2018 — Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
• Lin et al. JClinOncol 2018 — Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer
• Solomon et al. JClinOncol 2018 — Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in
• Kiura et al. JpnJClinOncol 2018 — Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and
• Nishio et al. LungCancer 2018 — Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive
• Camidge et al. NEnglJMed 2018 — Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
• Dardaei et al. NatMed 2018 — SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
• Lovly et al. AmSocClinOncolEducBook 2017 — Managing resistance to EFGR-and ALK-targeted therapies
• Woo et al. AnnOncol 2017 — Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced
• Lin et al. CancerDiscov 2017 — Targeting ALK Precision medicine takes on drug resistance
• Asao et al. ClinLungCancer 2017 — Sequential use of anaplastic lymphoma kinase inhibitors in japanese patients with ALK-rearranged non-small-cell lung
• Kim et al. JClinOncol 2017 — Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer A
• Tamura et al. JClinOncol 2017 — Three-year follow-up of an alectinib phase III study in ALK-positive non-small-cell lung cancer AF-001jp
• Cho et al. JThoracOncol 2017 — ASCEND-8 A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted
• Ito et al. JThoracOncol 2017 — Sequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer-A multicenter
• Hida et al. Lancet 2017 — Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) an open-label, randomised
• Soria et al. Lancet 2017 — First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer
• Shaw et al. LancetOncol 2017 — Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy
• Shaw et al. LancetOncol 2017 — Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement an international, multicentre, open-label,
• Califano et al. LungCancer 2017 — Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
• Peters et al. NEnglJMed 2017 — Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer
• Duruisseaux et al. Oncotarget 2017 — Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer
• Gainor et al. CancerDiscov 2016 — Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer
• Infarinato et al. CancerDiscov 2016 — The ALKROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma
• Zhang et al. ClinCancerRes 2016 — The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK
• Matikas et al. ClinLungCancer 2016 — Management of resistance to crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer
• Watanabe et al. ClinLungCancer 2016 — Progression-free and overall survival of patients with ALK rearrangement-positive non-small cell lung cancer treated
• Tsao et al. IASLC 2016 — Atlas of ALK and ROS1 Testing in Lung Cancer Second Edition
• Crino et al. JClinOncol 2016 — Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged
• Johung et al. JClinOncol 2016 — Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain
• Ou et al. JClinOncol 2016 — Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer A phase II global study
• Yoshida et al. JClinOncol 2016 — Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer
• Janne et al. JThoracOncol 2016 — Combined pan-HER and ALKROS1MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer
• Gettinger et al. LancetOncol 2016 — Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies a single-arm,
• Kim et al. LancetOncol 2016 — Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) updated results
• Shaw et al. LancetOncol 2016 — Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer a single-group, multicentre, phase 2 trial
• Yoshida et al. LungCancer 2016 — Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
• Shaw et al. NEnglJMed 2016 — Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F
• Hong et al. OncoImmunology 2016 — Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC implication for
• Koh et al. OncoImmunology 2016 — EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor
• Wilson et al. CancerCell 2015 — A functional landscape of resistance to ALK inhibition in lung cancer
• Zou et al. CancerCell 2015 — PF-06463922, an ALKROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical
• Toyokawa et al. CancerMetastasisRev 2015 — Insights into brain metastasis in patients with ALK+ lung cancer is the brain truly a sanctuary
• Gainor et al. ClinCancerRes 2015 — Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib
• Costa et al. JClinOncol 2015 — Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain
• Nishio et al. JThoracOncol 2015 — Phase I study of ceritinib (LDK378) in japanese patients with advanced, anaplastic lymphoma kinase-rearranged
• Chiari et al. LungCancer 2015 — Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer
• Chino et al. LungCancer 2015 — Successful treatment with alectinib after crizotinib-induced ILD
• Ou et al. AnnOncol 2014 — Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with
• Friboulet et al. CancerDiscov 2014 — The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
• Gridelli et al. CancerTreatRev 2014 — ALK inhibitors in the treatment of advanced NSCLC
• Katayama et al. ClinCancerRes 2014 — Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
• Jhaveri et al. ExpertOpinInvestigDrugs 2014 — Heat shock protein 90 inhibitors in the treatment of cancer current status and future directions
• Gadgeel et al. LancetOncol 2014 — Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant
• Shaw et al. NEnglJMed 2014 — Ceritinib in ALK-rearranged non-small-cell lung cancer
• Solomon et al. NEnglJMed 2014 — First-line crizotinib versus chemotherapy in ALK-positive lung cancer
• Lovly et al. NatMed 2014 — Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
• Shaw et al. AnnOncol 2013 — Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
• Ying et al. AnnOncol 2013 — Diagnostic value of a novel fully automated immunochimistry assay for detection of ALK rearrangement in primary lung …
• Gainor et al. ClinCancerRes 2013 — ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS an analysis of 1,683 patients with non-small
• Conklin et al. JThoracOncol 2013 — Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung
• Srivastava et al. JThoracOncol 2013 — Esophagitis a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer
• Seto et al. LancetOncol 2013 — CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001jp study) a
• Yang et al. LancetOncol 2013 — A selective ALK inhibitor in ALK-rearranged patients
• Selinger et al. ModPathol 2013 — Testing for ALK rearrangement in lung adenocarcinoma a multicenter comparison of immunohistochemistry and fluorescent
• Shaw et al. NEnglJMed 2013 — Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
• Lee et al. Cancer 2012 — Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type
• Doebele et al. ClinCancerRes 2012 — Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
• Camidge et al. LancetOncol 2012 — Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer updated results from a phase
• Katayama et al. SciTranslMed 2012 — Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
• Sakamoto et al. CancerCell 2011 — CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
• Shaw et al. ClinCancerRes 2011 — Targeting anaplastic lymphoma kinase in lung cancer
• Costa et al. JClinOncol 2011 — CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
• Cui et al. JMedChem 2011 — Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of
• Camidge et al. JThoracOncol 2011 — Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged
• Shaw et al. LancetOncol 2011 — Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene
• Katayama et al. ProcNatlAcadSciUSA 2011 — Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene
• Camidge et al. ClinCancerRes 2010 — Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements
• Ou et al. JThoracOncol 2010 — Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK
• Choi et al. NEnglJMed 2010 — EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
• Kwak et al. NEnglJMed 2010 — Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
• Wong et al. Cancer 2009 — The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR
• Takeuchi et al. ClinCancerRes 2009 — KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive L…
• Horn et al. JClinOncol 2009 — EML4-ALK honing in on a new target in non-small-cell lung cancer
• Shaw et al. JClinOncol 2009 — Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
• Choi et al. CancerRes 2008 — Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
• McDermott et al. CancerRes 2008 — Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
• Mano et al. CancerSci 2008 — Non-solid oncogenes in solid tumors EML4-ALK fusion genes in lung cancer
• Koivunen et al. ClinCancerRes 2008 — EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
• Takeuchi et al. ClinCancerRes 2008 — Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
• Inamura et al. JThoracOncol 2008 — EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
• Zou et al. CancerRes 2007 — An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through
• Soda et al. Nature 2007 — Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

Clinical-NSCLC-Driver negative

• Kim et al. Cancer 2026 — Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab tumor-specific
• Chien et al. CancerImmunolImmunother 2026 — Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lun…
• Shimizu et al. CancerSci 2026 — Atezolizumab + chemotherapy in older patients with lung cancer in japan
• Marinelli et al. CancerTreatRev 2026 — PD-(l)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy A
• Borghaei et al. ClinCancerRes 2026 — Early detriment analysis of first-line nivolumab plus ipilimumab-based therapy in patients with metastatic non-small
• Vujanovic et al. ClinCancerRes 2026 — Tumoral and systemic immune correlates of response to concurrent pembrolizumab and chemoradiotherapy in patients with
• Zamulko et al. ClinCancerRes 2026 — A phase 2 feasibility study combining pembrolizumab and metformin in patients with metastatic head and neck cancer
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy
• Han et al. FrontOncol 2026 — Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic
• Chaft et al. JAMA 2026 — Adjuvant nivolumab vs observation in resected Non-Small cell lung cancer
• DiFederico et al. JAMAOncol 2026 — PD-(l)1 inhibitor monotherapy vs chemoimmunotherapy
• Socinski et al. JAMAOncol 2026 — Tiragolumab plus atezolizumab and chemotherapy for advanced nonsquamous non-small cell lung cancer the phase 3
• Willmann et al. JClinOncol 2026 — Metastatic trajectories in non-small cell lung cancer guide local and systemic therapies
• Lee et al. JImmunotherCancer 2026 — Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck
• Ulas et al. JImmunotherCancer 2026 — Rescue by radiotherapy and anti-CTLA4PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC the
• Lu et al. Lancet 2026 — Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer
• Xiong et al. Lancet 2026 — Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer
• Shiraishi et al. LungCancer 2026 — Final overall survival analysis of the APPLE study atezolizumab and platinum-pemetrexed with or without bevacizumab for
• Provencio et al. NatCancer 2026 — Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC phase 3
• Huang et al. NatMed 2026 — Time-of-day immunochemotherapy in non-small cell lung cancer a randomized phase 3 trial
• Cengiz et al. SciRep 2026 — Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients
• Peruzzo et al. ClinLungCancer 2025 — Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1-negative squamous cell lung carcinoma A systematic review
• Carbone et al. ESMOOpen 2025 — Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung
• Rossi et al. ESMOOpen 2025 — Immunotherapy for resectable NSCLC neoadjuvantperioperative followed by surgery over surgery followed by adjuvant
• Fick et al. JThoracCardiovascSurg 2025 — High-risk features associated with recurrence in stage I lung adenocarcinoma
• Peters et al. JThoracOncol 2025 — Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic nsclc five-year
• Xiong et al. Lancet 2025 — Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (harmoni-2) a randomised, double-blind,
• DiFederico et al. LancetOncol 2025 — Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in
• Barlesi et al. OncoImmunology 2025 — Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer
• Altorki et al. CellRepMed 2024 — A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage
• Spicer et al. Lancet 2024 — Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy
• Garassino et al. JTOClinResRep 2023 — Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus
• Heymach et al. NEnglJMed 2023 — Perioperative durvalumab for resectable non-small-cell lung cancer
• Wakelee et al. NEnglJMed 2023 — Perioperative pembrolizumab for early-stage non-small-cell lung cancer
• Hanahan et al. CancerDiscov 2022 — Hallmarks of cancer New Dimensions
• Hummelink et al. ClinCancerRes 2022 — PD-1t TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC
• Rocha et al. ClinCancerRes 2022 — Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy, and chemoimmunotherapy in
• Gadgeel et al. ClinLungCancer 2022 — Comparison of SP142 and 22c3 immunohistochemistry PD-L1 assays for clinical efficacy of atezolizumab in non-small cell
• Gridelli et al. ESMOOpen 2022 — First-line immunotherapy in advanced NSCLC patients with ECOG PS 2 results of an international expert Panel meeting b…
• Hosokawa et al. IntJClinOncol 2022 — Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression OLCSG 1801
• Ricciuti et al. JAMAOncol 2022 — Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and
• Provencio et al. JClinOncol 2022 — Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA
• Casarrubios et al. JImmunotherCancer 2022 — Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in
• Saji et al. Lancet 2022 — Segmentectomy versus lobectomy in small-sized peripheral NSCLC JCOG0802 WJOG4607L
• Naranbhai et al. LancetOncol 2022 — HLA-a03 and response to immune checkpoint blockade in cancer an epidemiological biomarker study
• OBrien et al. LancetOncol 2022 — Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer
• Forde et al. NEnglJMed 2022 — Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
• Rodriguez-Abreu et al. AnnOncol 2021 — Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous
• Amrein et al. CancerImmunolImmunother 2021 — Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC SAKK19-09 study
• Nishio et al. CancerSci 2021 — IMpower132 Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
• Sakai et al. CancerSci 2021 — Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR)
• Satouchi et al. CancerSci 2021 — First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer KEYNOTE-024 japan subset
• Harding et al. ClinCancerRes 2021 — Blocking TIM-3 in treatment-refractory advanced solid tumors A phase iab study of LY3321367 with or without an
• Hellmann et al. ClinCancerRes 2021 — Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(l)1 therapy
• Reck et al. ESMOOpen 2021 — First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in
• Kim et al. EurJCancer 2021 — Dynamic changes in circulating PD-1+cd8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients
• Gettinger et al. JAMAOncol 2021 — Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer the
• Jabbour et al. JAMAOncol 2021 — Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III
• Skinner et al. JAMAOncol 2021 — Addition of metformin to concurrent chemoradiation in patients with locally advanced non-small cell lung cancer the
• Zenke et al. JAMAOncol 2021 — Effect of second-generation vs third-generation chemotherapy regimens with thoracic radiotherapy on unresectable stage
• Schlauch et al. JCOPrecisOncol 2021 — Tumor-specific and tumor-agnostic molecular signatures associated with response to immune checkpoint inhibitors
• Borghaei et al. JClinOncol 2021 — Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057 nivolumab versus docetaxel in previously
• Boyer et al. JClinOncol 2021 — Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score
• Reck et al. JClinOncol 2021 — Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor
• Hu et al. JImmunotherCancer 2021 — Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in
• Negrao et al. JImmunotherCancer 2021 — Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in
• Awad et al. JThoracOncol 2021 — Long-term overall survival from KEYNOTE-021 cohort G pemetrexed and carboplatin with or without pembrolizumab as
• Doroshow et al. JThoracOncol 2021 — Programmed death-ligand 1 tumor proportion score and overall survival from first-line pembrolizumab in patients with
• Faivre-Finn et al. JThoracOncol 2021 — Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial
• Hellyer et al. JThoracOncol 2021 — Role of consolidation durvalumab in patients with EGFR-and HER2-mutant unresectable stage III NSCLC
• Leighl et al. JThoracOncol 2021 — Meeting immunotherapy resistance in lung cancer
• Mazieres et al. JThoracOncol 2021 — Atezolizumab versus docetaxel in pretreated patients with NSCLC final results from the randomized phase 2 POPLAR and
• Nishio et al. JThoracOncol 2021 — Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC results from the randomized phase 3
• Powell et al. JThoracOncol 2021 — Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases pooled
• Shirasawa et al. JThoracOncol 2021 — Differential immune-related microenvironment determines programmed cell death protein-1programmed death-ligand 1
• Socinski et al. JThoracOncol 2021 — IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic
• Yoneshima et al. JThoracOncol 2021 — Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC
• Felip et al. Lancet 2021 — Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010) a
• Paz-Ares et al. LancetOncol 2021 — First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung
• Abbar et al. LungCancer 2021 — Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with
• Eichhorn et al. LungCancer 2021 — Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer first
• Faivre-Finn et al. LungCancer 2021 — Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC
• Forest et al. LungCancer 2021 — Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes
• Garon et al. LungCancer 2021 — Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung
• Lobefaro et al. LungCancer 2021 — Immunotherapy in advanced non-small cell lung cancer patients with poor performance status the role of
• Park et al. LungCancer 2021 — Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in
• Kaira et al. Medicina(Kaunas) 2021 — Clinical effectiveness of immune checkpoint inhibitors in non-small-cell lung cancer with a poor performance status
• Huang et al. ModPathol 2021 — A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite
• Wang et al. NatMed 2021 — Toward personalized treatment approaches for non-small-cell lung cancer
• Facchinetti et al. TranslLungCancerRes 2021 — First-line immunotherapy in non-small cell lung cancer patients with poor performance status a systematic review and
• Kaira et al. BMCCancer 2020 — A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer
• Sha et al. CancerDiscov 2020 — Tumor mutational burden as a predictive biomarker in solid tumors
• Ozaki et al. CancerImmunolImmunother 2020 — Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint
• Frost et al. ClinLungCancer 2020 — Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1
• Garon et al. ESMOOpen 2020 — Exploratory analysis of front-line therapies in REVEL a randomised phase 3 study of ramucirumab plus docetaxel versus
• Facchinetti et al. EurJCancer 2020 — First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
• Felip et al. EurJCancer 2020 — CheckMate 171 A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung
• Lala et al. EurJCancer 2020 — A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and
• Wiesweg et al. EurJCancer 2020 — Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by
• Duan et al. JAMAOncol 2020 — Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer
• Dummer et al. JAMAOncol 2020 — Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma A review
• Jabbour et al. JAMAOncol 2020 — Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell
• Pathak et al. JAMAOncol 2020 — Association of survival with adjuvant chemotherapy among patients with early-stage non-small cell lung cancer with vs
• Rizvi et al. JAMAOncol 2020 — Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell
• Gadgeel et al. JClinOncol 2020 — Updated analysis from KEYNOTE-189 pembrolizumab or placebo plus pemetrexed and platinum for previously untreated
• Kenmotsu et al. JClinOncol 2020 — Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage
• Waterhouse et al. JClinOncol 2020 — Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer CheckMate
• Kato et al. JImmunotherCancer 2020 — Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with
• Reuss et al. JImmunotherCancer 2020 — Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
• Miyawaki et al. JTOClinResRep 2020 — Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC
• Gray et al. JThoracOncol 2020 — Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC
• Jotte et al. JThoracOncol 2020 — Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131) results from a
• Lantuejoul et al. JThoracOncol 2020 — Interobserver reliability of programmed cell death ligand-1 scoring using the VENTANA PD-L1 (SP263) assay in NSCLC
• Paz-Ares et al. JThoracOncol 2020 — A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC
• Garassino et al. LancetOncol 2020 — Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously
• Goldberg et al. LancetOncol 2020 — Pembrolizumab for management of patients with NSCLC and brain metastases long-term results and biomarker analysis from
• Middleton et al. LancetRespirMed 2020 — Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2) a single arm, phase 2 trial
• DallOlio et al. LungCancer 2020 — ECOG performance status 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with
• Herbst et al. NEnglJMed 2020 — Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC
• Barlesi et al. OncoImmunology 2020 — Effectiveness and safety of nivolumab in the treatment of lung cancer patients in france preliminary results from the
• Spicer et al. AnnThoracSurg 2019 — Multimodality therapy for N2 non-small cell lung cancer an evolving paradigm
• Harada et al. AnticancerRes 2019 — Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination
• Trinh et al. CancerCell 2019 — Tumor neoantigens When too much of a good thing is bad
• Doroshow et al. ClinCancerRes 2019 — Immunotherapy in non-small cell lung cancer facts and hopes
• Basak et al. EurJCancer 2019 — Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer
• Sugawara et al. IntJClinOncol 2019 — Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after
• Salem et al. JAMAOncol 2019 — Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III Small Cell Lung Cancer
• Theelen et al. JAMAOncol 2019 — Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with
• Garon et al. JClinOncol 2019 — Five-year overall survival for patients with advanced Non-Small-cell lung cancer treated with pembrolizumab results
• Passaro et al. JClinOncol 2019 — Immunotherapy in non-small-cell lung cancer patients with performance status 2 clinical decision making with scant
• Ramalingam et al. JClinOncol 2019 — Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer
• Ready et al. JClinOncol 2019 — First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568) outcomes by programmed
• Reck et al. JClinOncol 2019 — Updated analysis of KEYNOTE-024 pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung
• Jin et al. JThoracOncol 2019 — The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in
• Spigel et al. JThoracOncol 2019 — Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients
• Mok et al. Lancet 2019 — Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic
• West et al. LancetOncol 2019 — Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as
• Assoun et al. LungCancer 2019 — Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced
• Crino et al. LungCancer 2019 — Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
• Galli et al. LungCancer 2019 — Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
• Gubens et al. LungCancer 2019 — Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer
• Nosaki et al. LungCancer 2019 — Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung
• Oyanagi et al. LungCancer 2019 — Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
• Park et al. LungCancer 2019 — A phase ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
• Takano et al. LungCancer 2019 — Improvement in the survival of patients with stage IV non-small-cell lung cancer experience in a single institutional
• Wang et al. LungCancer 2019 — Erratum to the metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma
• Hellmann et al. NEnglJMed 2019 — Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
• Rauer et al. NEnglJMed 2019 — Treatment of progressive multifocal leukoencephalopathy with pembrolizumab
• Walter et al. NEnglJMed 2019 — Treatment of progressive multifocal leukoencephalopathy with nivolumab
• Samstein et al. NatGenet 2019 — Tumor mutational load predicts survival after immunotherapy across multiple cancer types
• Arimura et al. RespirRes 2019 — Comparison of tumor cell numbers and 22c3 PD-L1 expression between cryobiopsy and transbronchial biopsy with
• Shiono et al. ThoracCancer 2019 — Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung
• Planchard et al. AnnOncol 2018 — Metastatic non-small cell lung cancer ESMO clinical practice guidelines for diagnosis, treatment and follow-up
• Tanaka et al. AnnThoracSurg 2018 — Induction chemoradiotherapy (50 gy), followed by resection, for stage IIIA-N2 non-small cell lung cancer
• Skoulidis et al. CancerDiscov 2018 — STK11LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
• Biton et al. ClinCancerRes 2018 — TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma
• Kim et al. ClinCancerRes 2018 — Abemaciclib in combination with single-agent options in patients with stage IV non-small cell lung cancer A phase ib
• McCall et al. ClinCancerRes 2018 — Beyond concurrent chemoradiation the emerging role of PD-1pd-L1 inhibitors in stage III lung cancer
• Atagi et al. ClinLungCancer 2018 — Chemoradiotherapy in elderly patients with non-small-cell lung cancer long-term follow-up of a randomized trial
• Ciuleanu et al. ClinLungCancer 2018 — Efficacy and safety of necitumumab continuation therapy in the phase III SQUIRE study of patients with stage IV
• Ramalingam et al. ClinLungCancer 2018 — Efficacy and safety of ramucirumab with docetaxel versus placebo with docetaxel as second-line treatment of advanced
• Horn et al. EurJCancer 2018 — Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer final results from a
• Gridelli et al. JAMAOncol 2018 — Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced
• Gettinger et al. JClinOncol 2018 — Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer results from the CA209-003
• Rizvi et al. JClinOncol 2018 — Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1)
• Fehrenbacher et al. JThoracOncol 2018 — Updated efficacy analysis including secondary population results for OAK A randomized phase III study of atezolizumab
• Genova et al. JThoracOncol 2018 — EGFR gene copy number by FISH may predict outcome of necitumumab in squamous lung carcinomas analysis from the SQUIRE
• Tsao et al. JThoracOncol 2018 — PD-L1 immunohistochemistry comparability study in real-life clinical samples results of blueprint phase 2 project
• Herbst et al. LancetOncol 2018 — Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without
• Kawano et al. LungCancer 2018 — Phase III study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced
• Antonia et al. NEnglJMed 2018 — Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
• Forde et al. NEnglJMed 2018 — Neoadjuvant PD-1 blockade in resectable lung cancer
• Gandhi et al. NEnglJMed 2018 — Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
• Hellmann et al. NEnglJMed 2018 — Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
• Paz-Ares et al. NEnglJMed 2018 — Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
• Socinski et al. NEnglJMed 2018 — Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
• Jarchum et al. NatBiotechnol 2018 — Putting a number on neoepitope quality
• Ngwa et al. NatRevCancer 2018 — Using immunotherapy to boost the abscopal effect
• Cristescu et al. Science 2018 — Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
• Zitvogel et al. Science 2018 — The microbiome in cancer immunotherapy Diagnostic tools and therapeutic strategies
• Nokihara et al. AnnOncol 2017 — Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with
• Tang et al. AnnOncol 2017 — Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical
• Chaft et al. AnnThoracSurg 2017 — Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors
• Anagnostou et al. CancerDiscov 2017 — Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer
• Ratcliffe et al. ClinCancerRes 2017 — Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in
• Nakamichi et al. ClinLungCancer 2017 — Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing
• Shiran et al. ClinLungCancer 2017 — Non-small-cell lung cancer patients with adenocarcinoma morphology have a better outcome compared with patients
• Su et al. EurJCancer 2017 — Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced non-small cell lung cancer
• Tabchi et al. FrontOncol 2017 — Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine
• Salazar et al. JAMAOncol 2017 — Association of delayed adjuvant chemotherapy with survival after lung cancer surgery
• Hanna et al. JClinOncol 2017 — Systemic therapy for stage IV non-small-cell lung cancer american society of clinical oncology clinical practice
• Horn et al. JClinOncol 2017 — Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer two-year outcomes
• Peters et al. JClinOncol 2017 — Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected
• Evison et al. JThoracOncol 2017 — Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy an update by the british
• Marchetti et al. JThoracOncol 2017 — Multicenter comparison of 22c3 PharmDx (agilent) and SP263 (ventana) assays to test PD-L1 expression for NSCLC patients
• Watanabe et al. JpnJClinOncol 2017 — Neoadjuvant and adjuvant therapy for stage III non-small cell lung cancer
• Rittmeyer et al. Lancet 2017 — Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) a phase 3,
• Hellmann et al. LancetOncol 2017 — Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012) results of an
• Shaverdian et al. LancetOncol 2017 — Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung
• Wakelee et al. LancetOncol 2017 — Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505) an
• Fujimoto et al. LungCancer 2017 — A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial
• Paz-Ares et al. LungCancer 2017 — Treatment outcomes by histology in REVEL A randomized phase III trial of ramucirumab plus docetaxel for advanced
• Reck et al. LungCancer 2017 — Outcomes in patients with aggressive or refractory disease from REVEL A randomized phase III study of docetaxel with
• Goodman et al. MolCancerTher 2017 — Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
• Antonia et al. NEnglJMed 2017 — Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
• Carbone et al. NEnglJMed 2017 — First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
• Yarchoan et al. NEnglJMed 2017 — Tumor mutational burden and response rate to PD-1 inhibition
• Janzic et al. RadiolOncol 2017 — PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
• Fiala et al. TumourBiol 2017 — Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung
• Chatterjee et al. AnnOncol 2016 — Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
• Kanda et al. AnnOncol 2016 — Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell
• Paz-Ares et al. AnnOncol 2016 — Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE a randomized, multicenter, open-label, phase
• Nishio et al. ESMOOpen 2016 — Multicentre phase II study of nivolumab in japanese patients with advanced or recurrent non-squamous non-small cell
• Gettinger et al. JClinOncol 2016 — Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer
• Rizvi et al. JClinOncol 2016 — Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell
• Shukuya et al. JThoracOncol 2016 — Predictive markers for the efficacy of anti-PD-1pd-L1 antibodies in lung cancer
• Fehrenbacher et al. Lancet 2016 — Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR) a multicentre,
• Herbst et al. Lancet 2016 — Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer
• Antonia et al. LancetOncol 2016 — Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer a multicentre, phase 1b
• Gomez et al. LancetOncol 2016 — Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell
• Langer et al. LancetOncol 2016 — Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer a
• Weber et al. LancetOncol 2016 — Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma
• Dudnik et al. LungCancer 2016 — Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
• Sakata et al. LungCancer 2016 — Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer kumamoto thoracic
• Yoh et al. LungCancer 2016 — A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in japanese patients
• Reck et al. NEnglJMed 2016 — Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
• Eberhardt et al. AnnOncol 2015 — 2nd ESMO consensus conference in lung cancer locally advanced stage III non-small-cell lung cancer
• Kubota et al. AnnOncol 2015 — A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in japanese patients with
• Li et al. AnnOncol 2015 — Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage
• Malhotra et al. AnnOncol 2015 — Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer 4 cm in size an SEER-medicare
• Berry et al. AnnSurgOncol 2015 — Benefit of adjuvant chemotherapy after resection of stage II (T1-2n1m0) non-small cell lung cancer in elderly patients
• Tamura et al. BMCResNotes 2015 — Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary
• Anagnostou et al. ClinCancerRes 2015 — Cancer immunotherapy a future paradigm shift in the treatment of non-small cell lung cancer
• vanElsas et al. ClinCancerRes 2015 — Translating pembrolizumab to clinical practice speak immunology and learn fast!
• Galetta et al. ClinLungCancer 2015 — CisplatinPemetrexed followed by maintenance pemetrexed versus CarboplatinPaclitaxelBevacizumab followed by maintenance
• Speicher et al. EurJCardiothoracSurg 2015 — Outcomes after treatment of 17,378 patients with locally advanced (T3N0-2) non-small-cell lung cancer
• Nagata et al. IntJRadiatOncolBiolPhys 2015 — Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung
• Abe et al. JClinOncol 2015 — Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in
• Eberhardt et al. JClinOncol 2015 — Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage
• Gettinger et al. JClinOncol 2015 — Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients
• Postow et al. JClinOncol 2015 — Immune checkpoint blockade in cancer therapy
• Robinson et al. JClinOncol 2015 — Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy a review of
• Santana-Davila et al. JClinOncol 2015 — Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell
• Tsao et al. JClinOncol 2015 — Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing
• Hung et al. JThoracOncol 2015 — Prognostic factors of survival after recurrence in patients with resected lung adenocarcinoma
• Noonan et al. JThoracOncol 2015 — The influence of the evolution of first-line chemotherapy on steadily improving survival in advanced non-small-cell
• Zinner et al. JThoracOncol 2015 — PRONOUNCE randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance
• Pless et al. Lancet 2015 — Induction chemoradiation in stage IIIAN2 non-small-cell lung cancer a phase 3 randomised trial
• Bradley et al. LancetOncol 2015 — Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel
• Golden et al. LancetOncol 2015 — Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with
• Rizvi et al. LancetOncol 2015 — Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory
• Shukuya et al. LancetOncol 2015 — Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung
• Soria et al. LancetOncol 2015 — Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung
• Thatcher et al. LancetOncol 2015 — Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients
• Weber et al. LancetOncol 2015 — Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-ctla-4 treatment (checkmate
• Cooper et al. LungCancer 2015 — PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
• Kim et al. LungCancer 2015 — Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma comparison with
• Borghaei et al. NEnglJMed 2015 — Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
• Brahmer et al. NEnglJMed 2015 — Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
• Garon et al. NEnglJMed 2015 — Pembrolizumab for the treatment of non-small-cell lung cancer
• Larkin et al. NEnglJMed 2015 — Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
• Le et al. NEnglJMed 2015 — PD-1 blockade in tumors with mismatch-repair deficiency
• Campesato et al. Oncotarget 2015 — Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade
• Imai et al. SpringerPlus 2015 — Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer
• Rotolo et al. AnnOncol 2014 — Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer new insights into the effect on failure type via a
• Ayyoub et al. CancerImmunolRes 2014 — Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and
• Viudez et al. CritRevOncolHematol 2014 — Nab-paclitaxel A flattering facelift
• Hung et al. JClinOncol 2014 — Predictive value of the international association for the study of lung canceramerican thoracic SocietyEuropean
• Langer et al. JClinOncol 2014 — Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel
• Garon et al. Lancet 2014 — Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung
• Mok et al. Lancet 2014 — A REVELation in non-small-cell lung cancer treatment
• NSCLC et al. Lancet 2014 — Preoperative chemotherapy for NSCLC A systematic review and meta-analysis of individual participant data
• Reck et al. LancetOncol 2014 — Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer
• Aprile et al. OncoTargetsTher 2014 — Ramucirumab Preclinical research and clinical development
• Socinski et al. AnnOncol 2013 — Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line
• Yoshioka et al. AnnOncol 2013 — Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy
• Paramanathan et al. ClinLungCancer 2013 — Patients treated with platinum-doublet chemotherapy for advanced non-small-cell lung cancer have inferior outcomes if
• deCastria et al. CochraneDatabaseSystRev 2013 — Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
• Barlesi et al. JClinOncol 2013 — Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with
• Patel et al. JClinOncol 2013 — PointBreak a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance
• Paz-Ares et al. JClinOncol 2013 — PARAMOUNT final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately
• Zukin et al. JClinOncol 2013 — Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced
• Hoang et al. LungCancer 2013 — Histology based analysis of E1594
• Satouchi et al. LungCancer 2013 — Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer
• Taylor et al. AnnThoracSurg 2012 — Tumor recurrence after complete resection for non-small cell lung cancer
• Katakami et al. Cancer 2012 — A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients
• Zhu et al. JAMA 2012 — Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer
• Ardizzoni et al. JClinOncol 2012 — Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer results
• Socinski et al. JClinOncol 2012 — Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line
• Spigel et al. JThoracOncol 2012 — A randomized phase II trial of pemetrexedgemcitabinebevacizumab or pemetrexedcarboplatinbevacizumab in the first-line
• Wakelee et al. JThoracOncol 2012 — A Double-Blind Randomized Discontinuation Phase-II Trial of sorafenib (BAY 43-9006)
• Atagi et al. LancetOncol 2012 — Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer a
• Paz-Ares et al. LancetOncol 2012 — Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction
• Ohguri et al. LungCancer 2012 — Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer a potential modality for inducing
• Brahmer et al. NEnglJMed 2012 — Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
• Wisnivesky et al. BMJ 2011 — Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages
• Galetta et al. ClinLungCancer 2011 — Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus
• Quoix et al. Lancet 2011 — Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced
• Bennouna et al. LungCancer 2011 — Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy subgroup
• Reck et al. AnnOncol 2010 — Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous
• Non et al. CochraneDatabaseSystRev 2010 — Small-Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer
• Arriagada et al. JClinOncol 2010 — Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in
• Butts et al. JClinOncol 2010 — Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and
• Dahlberg et al. JClinOncol 2010 — Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with
• Felip et al. JClinOncol 2010 — Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage
• Okamoto et al. JClinOncol 2010 — Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients
• Yamamoto et al. JClinOncol 2010 — Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with
• Clement et al. JThoracOncol 2010 — Duchene-A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-sm…
• Douillard et al. JThoracOncol 2010 — Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer subgroup analysis of the lung
• Leighl et al. JThoracOncol 2010 — Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small
• Sandler et al. JThoracOncol 2010 — Histology subset of ECOG4599
• Kim et al. LungCancer 2010 — A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small
• Gronberg et al. JClinOncol 2009 — Phase III study by the norwegian lung cancer study group pemetrexed plus carboplatin compared with gemcitabine plus
• Patel et al. JClinOncol 2009 — Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line
• Reck et al. JClinOncol 2009 — Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous
• Smit et al. JClinOncol 2009 — Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated
• Hamada et al. JThoracOncol 2009 — UFT on stage IA NSCLC
• Albain et al. Lancet 2009 — Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer a phase III
• Ciuleanu et al. Lancet 2009 — Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung
• Scagliotti et al. Oncologist 2009 — The differential efficacy of pemetrexed according to NSCLC histology a review of two phase III studies
• NSCLC et al. JClinOncol 2008 — Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer a systematic
• Pignon et al. JClinOncol 2008 — Lung adjuvant cisplatin evaluation a pooled analysis by the LACE collaborative group
• Ramalingam et al. JClinOncol 2008 — Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with
• Scagliotti et al. JClinOncol 2008 — Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with
• Strauss et al. JClinOncol 2008 — Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer CALGB 9633 with
• Naito et al. JThoracOncol 2008 — Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer
• Ohe et al. AnnOncol 2007 — Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine,
• Gridelli et al. JClinOncol 2007 — Lung cancer in the elderly
• Langer et al. JClinOncol 2007 — Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology
• Park et al. JClinOncol 2007 — Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of
• Pepe et al. JClinOncol 2007 — Adjuvant vinorelbine and cisplatin in elderly patients national cancer institute of canada and intergroup study JBR.10
• Ardizzoni et al. JNatlCancerInst 2007 — Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer an
• vanMeerbeeck et al. JNatlCancerInst 2007 — Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2
• Gridelli et al. AnnOncol 2006 — Chemotherapy of advanced NSCLC in special patient population
• Desai et al. ClinCancerRes 2006 — Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free,
• Sekine et al. JThoracOncol 2006 — Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with
• Douillard et al. LancetOncol 2006 — Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA
• Sandler et al. NEnglJMed 2006 — Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
• Nakagawa et al. AnnOncol 2005 — A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I
• Manser et al. CochraneDatabaseSystRev 2005 — Surgery for early stage non-small cell lung cancer
• Sugiura et al. InvestNewDrugs 2005 — Phase III study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer
• Belani et al. JClinOncol 2005 — Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer a
• Hamada et al. JClinOncol 2005 — Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer
• Hoang et al. JClinOncol 2005 — Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with
• Lilenbaum et al. JClinOncol 2005 — Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer the cancer and leukemia group B
• Okamoto et al. JpnJClinOncol 2005 — Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung
• Montero et al. LancetOncol 2005 — Docetaxel for treatment of solid tumours a systematic review of clinical data
• Alam et al. LungCancer 2005 — Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. an analysis of national cancer
• Winton et al. NEnglJMed 2005 — Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
• Gridelli et al. AnnOncol 2004 — Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2 results of an european experts
• Sekine et al. CancerSci 2004 — Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell
• Hanna et al. JClinOncol 2004 — Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously
• Johnson et al. JClinOncol 2004 — Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone
• Arriagada et al. NEnglJMed 2004 — Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
• Kato et al. NEnglJMed 2004 — A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
• Tsujino et al. IntJRadiatOncolBiolPhys 2003 — Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent
• Rosell et al. AnnOncol 2002 — Phase III randomised trial comparing paclitaxelcarboplatin with paclitaxelcisplatin in patients with advanced
• Langer et al. JNatlCancerInst 2002 — Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer implications of eastern
• Schiller et al. NEnglJMed 2002 — Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
• Sweeney et al. Cancer 2001 — Outcome of patients with a performance status of 2 in eastern cooperative oncology group study E1594 a phase II trial
• Kelly et al. JClinOncol 2001 — Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of
• Anderson et al. BrJCancer 2000 — Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with
• Gregory et al. BrJCancer 2000 — Vinorelbine-a clinical review
• Okamoto et al. IntJClinOncol 2000 — Phase II study of cisplatin and docetaxel combination chemotherapy in untreated advanced non-small cell lung cancer
• Fossella et al. JClinOncol 2000 — Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung
• Shepherd et al. JClinOncol 2000 — Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer
• Wada et al. EurJCardiothoracSurg 1999 — Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in
• Cullen et al. JClinOncol 1999 — Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer effects on survival and quality of life
• Crawford et al. JClinOncol 1996 — Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell
• Kunitoh et al. JClinOncol 1996 — Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer a japanese cooperative study
• Wada et al. JClinOncol 1996 — Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. west japan study group for lung cancer
• NSCLCMetaAnalyses et al. BMJ 1995 — Chemotherapy in non-small cell lung cancer-a meta-analysis using updated data on individual patients
• Taguchi et al. GanToKagakuRyoho 1994 — Late phase II clinical study of RP56976 (docetaxel) in patients with advancedrecurrent breast cancer
• Albain et al. JClinOncol 1991 — Survival determinants in extensive-stage non-small-cell lung cancer the southwest oncology group experience
• Bonomi et al. JClinOncol 1989 — Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung
• Rapp et al. JClinOncol 1988 — Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a canadian multicenter

Clinical-NSCLC-Driver-Other

• Wang et al. Cell 2026 — Farnesylation-driven KRAS phase separation promotes colon tumor growth
• Ruge et al. ClinCancerRes 2026 — Molecular and clinical characteristics of patients with NSCLC harboring KRAS Q61 mutations to assess therapeutic resp…
• Kropf-Sanchen et al. ClinLungCancer 2026 — A retrospective, multicenter analysis within the national network genomic medicine lung cancer in germany to detect RET
• Canaslan et al. CritRevOncolHematol 2026 — From G12C to pan-RAS the expanding therapeutic landscape of KRAS-mutant NSCLC
• Vitale et al. CritRevOncolHematol 2026 — Targeting KRAS G12C in non-small cell lung cancer breakthrough inhibitors and combination approaches
• Liang et al. FrontOncol 2026 — KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell lung cancer a pooled analysis of
• Sharma et al. JClinOncol 2026 — Phase I study of telisotuzumab adizutecan (temab-A, ABBV-400), a novel c-met antibody-drug conjugate, in patients with
• He et al. JNatlCancerCent 2026 — Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain
• Zhao et al. LungCancer 2026 — Clinical outcomes and tumor immune microenvironment in SMARCA4-deficient NSCLC A real-world retrospective study
• Luo et al. Med 2026 — Nsclc five trials to watch
• Park et al. NEnglJMed 2026 — Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer
• Wu et al. NEnglJMed 2026 — Selpercatinib in early-stage RET fusion-positive non-small-cell lung cancer
• Tishina et al. NatCommun 2026 — Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis
• Caswell et al. TrendsCancer 2026 — Lung cancer in never smokers from early detection to prevention
• Tong et al. CancerCell 2024 — Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
• Park et al. CancerRes 2024 — Proteogenomic characterization reveals estrogen signaling as a target for never-smoker lung adenocarcinoma patients
• Zhou et al. NEnglJMed 2023 — First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC
• Zeissig et al. TrendsCancer 2023 — Next batter up! targeting cancers with KRAS-G12D mutations
• Le et al. ClinCancerRes 2022 — Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC outcomes in patient subgroups from the VISION
• Hallin et al. NatMed 2022 — Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
• Arbour et al. ClinCancerRes 2021 — Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer
• Jones et al. ClinCancerRes 2021 — KRAS G12C mutation is associated with increased risk of recurrence in surgically resected lung adenocarcinoma
• Solanki et al. ClinCancerRes 2021 — Cell type-specific adaptive signaling responses to KRASG12C inhibition
• Zhang et al. JImmunotherCancer 2021 — Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant
• Finn et al. JThoracOncol 2021 — Prognostic impact of KRAS G12C mutation in patients with NSCLC results from the european thoracic oncology platform
• Sebastian et al. LungCancer 2021 — KRAS G12C-mutated advanced non-small cell lung cancer A real-world cohort from the german prospective, observational,
• Wong et al. LungCancer 2021 — MET exon 14 skipping mutation positive non-small cell lung cancer response to systemic therapy
• Kishikawa et al. ModPathol 2021 — Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma
• Skoulidis et al. NEnglJMed 2021 — Sotorasib for lung cancers with KRAS p.g12c mutation
• Zhang et al. NatGenet 2021 — Genomic and evolutionary classification of lung cancer in never smokers
• OLeary et al. NatRevCancer 2021 — Tracing the origins of KRAS oncogene addiction
• Mazieres et al. AnnOncol 2020 — Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
• Li et al. CancerDiscov 2020 — In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in KRAS-mutant lung adenocarcinoma
• Liu et al. CancerDrugResist 2020 — RET kinase alterations in targeted cancer therapy
• Kim et al. Cell 2020 — Targeting KRAS(G12C) from inhibitory mechanism to modulation of antitumor effects in patients
• Recondo et al. ClinCancerRes 2020 — Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC
• Lee et al. JCOPrecisOncol 2020 — Combined CDK4 6 and PD1 inhibition in refractory SMARCA4-deficient SCLC of the ovary
• Doebele et al. LancetOncol 2020 — Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours integrated analysis of three
• Hong et al. LancetOncol 2020 — Larotrectinib in patients with TRK fusion-positive solid tumours a pooled analysis of three phase 12 clinical trials
• Drilon et al. NEnglJMed 2020 — Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer
• Hong et al. NEnglJMed 2020 — KRASG12C inhibition with sotorasib in advanced solid tumors
• Paik et al. NEnglJMed 2020 — Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
• Wolf et al. NEnglJMed 2020 — Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer
• Drilon et al. NatMed 2020 — Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
• Bylicki et al. OncoTargetsTher 2020 — Targeting the MET-signaling pathway in NSCLC
• Kessler et al. ProcNatlAcadSciUSA 2020 — The hanging heart How KRAS lures its prey to the membrane
• Perret et al. AmJSurgPathol 2019 — SMARCA4-deficient thoracic sarcomas clinicopathologic study of 30 cases with an emphasis on their nosology and
• Hong et al. AnnOncol 2019 — Larotrectinib in adult patients with solid tumours a multi-centre, open-label, phase I dose-escalation study
• Schrock et al. AnnOncol 2019 — Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal
• Liao et al. CancerCell 2019 — KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
• Kitajima et al. CancerDiscov 2019 — Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
• Roman et al. CancerRes 2019 — Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung
• Solomon et al. CancerRes 2019 — Detection of NTRK fusions Merits and limitations of current diagnostic platforms
• Huang et al. Cell 2019 — A tumor-agnostic NTRK (TRK) inhibitor
• Jonna et al. ClinCancerRes 2019 — Detection of NRG1 gene fusions in solid tumors
• Stein et al. JCOPrecisOncol 2019 — Dual checkpoint inhibition an approach for STK11 and KRAS co-mutated lung adenocarcinoma
• Xue et al. NatCommun 2019 — SMARCA4 loss is synthetic lethal with CDK46 inhibition in non-small cell lung cancer
• Lung et al. PLoSONE 2019 — MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
• Subbiah et al. CancerDiscov 2018 — Precision targeted therapy with BLU-667 for RET-driven cancers
• Arbour et al. ClinCancerRes 2018 — Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer
• Wang et al. ClinCancerRes 2018 — Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer
• Drilon et al. NEnglJMed 2018 — Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
• Nakaoku et al. NatCommun 2018 — A secondary RET mutation in the activation loop conferring resistance to vandetanib
• Cocco et al. NatRevClinOncol 2018 — NTRK fusion-positive cancers and TRK inhibitor therapy
• Hyman et al. JClinOncol 2017 — AKT inhibition in solid tumors with AKT1 mutations
• Planchard et al. LancetOncol 2017 — Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer
• Zehir et al. NatMed 2017 — Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
• Inamura et al. Oncotarget 2017 — Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes
• Plenker et al. SciTranslMed 2017 — Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
• Trusolino et al. CancerDiscov 2016 — Oncogenic MET as an effective therapeutic target in non-small cell lung cancer resistant to EGFR inhibitors the rise of
• Awad et al. JClinOncol 2016 — MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic
• Liu et al. JClinOncol 2016 — Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations
• Menichincheri et al. JMedChem 2016 — Discovery of entrectinib A new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase
• Schrock et al. JThoracOncol 2016 — Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
• Planchard et al. LancetOncol 2016 — Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer a single-arm, multicentre,
• Doebele et al. CancerDiscov 2015 — An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase
• Skoulidis et al. CancerDiscov 2015 — Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune
• Vaishnavi et al. CancerDiscov 2015 — TRKing down an old oncogene in a new era of targeted therapy
• Fernandez-Cuesta et al. ClinCancerRes 2015 — Molecular pathways targeting NRG1 fusions in lung cancer
• Tolcher et al. ClinCancerRes 2015 — Antitumor activity in RAS-driven tumors by blocking AKT and MEK
• Farago et al. JThoracOncol 2015 — Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer
• Nakaoku et al. ClinCancerRes 2014 — Druggable oncogene fusions in invasive mucinous lung adenocarcinoma
• Vasan et al. ClinCancerRes 2014 — A RAS renaissance emerging targeted therapies for KRAS-mutated non-small cell lung cancer
• Kris et al. JAMA 2014 — Using multiplexed assay of oncogenic drives in lung cancer
• Kahlert et al. JBiolChem 2014 — Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum
• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management
• Lin et al. ProcNatlAcadSciUSA 2014 — Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
• Cardarella et al. ClinCancerRes 2013 — Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer
• Kim et al. LungCancer 2013 — Personalized therapy on the horizon for squamous cell carcinoma of the lung
• Vaishnavi et al. NatMed 2013 — Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
• Hatzivassiliou et al. Nature 2013 — Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers
• Kohno et al. NatMed 2012 — KIF5B-RET fusions in lung adenocarcinoma
• Lipson et al. NatMed 2012 — Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
• Takeuchi et al. NatMed 2012 — RET, ROS1 and ALK fusions in lung cancer
• Marchetti et al. JClinOncol 2011 — Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations
• Paik et al. JClinOncol 2011 — Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations
• Bronte et al. CancerTreatRev 2010 — Driver mutations and differential sensitivity to targeted therapies a new approach to the treatment of lung
• Barbie et al. Nature 2009 — Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Clinical-NSCLC-EGFR

• Passiglia et al. Cancer 2026 — Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
• Vuong et al. CancerCell 2026 — Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma
• Piotrowska et al. CancerDiscov 2026 — ELIOS A multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated
• Zhao et al. CancerTreatRev 2026 — Perioperative strategies for resectable EGFR-mutant NSCLC evidence hierarchy and clinical decision-making
• Lu et al. ClinLungCancer 2026 — Characteristics and clinical outcomes of de novo and acquired uncommon compound EGFR mutations in patients with
• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following
• Kim et al. FrontOncol 2026 — Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC
• HARMONi et al. JAMA 2026 — A-Bispecific antibody ivonescimab added to chemotherapy in EGFR-variant non-small cell lung cancer the HARMONi-A
• Li et al. LancetOncol 2026 — Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2) an open-label,
• Okamoto et al. LungCancer 2026 — Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and
• Wang et al. LungCancer 2026 — Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance A real-world study of chinese patients
• Janne et al. NEnglJMed 2026 — Survival with osimertinib plus chemotherapy in EGFR-mutated advanced nsclc
• Zhou et al. NEnglJMed 2026 — First-line sunvozertinib in NSCLC with
• Remon et al. NatRevClinOncol 2026 — Unresectable stage III non-small-cell lung cancer state of the art and challenges
• Zhao et al. NatRevClinOncol 2026 — Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC-mechanisms and evolving treatment approaches
• Yang et al. NEnglJMed 2025 — Overall survival with amivantamab-lazertinib in EGFR-Mutated advanced NSCLC
• Watanabe et al. EurJCancer 2024 — A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC
• Cho et al. NEnglJMed 2024 — Amivantamab plus lazertinib in previously untreated EGFR-Mutated advanced NSCLC
• Zhou et al. NEnglJMed 2023 — Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions
• Soltis et al. CellRepMed 2022 — Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically
• Nogami et al. JThoracOncol 2022 — IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups
• Chang et al. NatBiotechnol 2022 — Identifying transcriptional programs underlying cancer drug response with TraCe-seq
• Tanaka et al. CancerCell 2021 — Targeting aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM-and
• Kashima et al. CancerRes 2021 — Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer
• Choudhury et al. ClinCancerRes 2021 — Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon
• Akamatsu et al. JAMAOncol 2021 — Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer
• Park et al. JClinOncol 2021 — Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy initial
• Aredo et al. JThoracOncol 2021 — Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy
• Shields et al. JThoracOncol 2021 — Selpercatinib overcomes CCDC6-RET-mediated resistance to osimertinib
• Hirose et al. LungCancer 2021 — Extensive functional evaluation of exon 20 insertion mutations of EGFR
• Kumagai et al. NatRevCancer 2021 — Antitumour immunity regulated by aberrant ERBB family signalling
• Robichaux et al. Nature 2021 — Structure-based classification predicts drug response in EGFR-mutant NSCLC
• Park et al. AnnOncol 2020 — A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer
• Yun et al. CancerDiscov 2020 — Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20
• Nishio et al. CancerSci 2020 — Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer east asian subset of RELAY
• Schoenfeld et al. ClinCancerRes 2020 — Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line
• Xing et al. ClinCancerRes 2020 — Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and
• Cho et al. JClinOncol 2020 — Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations A multicenter, open-label,
• Goldberg et al. JClinOncol 2020 — Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant
• Hosomi et al. JClinOncol 2020 — Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor
• Yang et al. JClinOncol 2020 — Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and
• Haratake et al. JTOClinResRep 2020 — Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in
• Ahn et al. JThoracOncol 2020 — Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC the AURA
• Sequist et al. LancetOncol 2020 — Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after
• Lin et al. LungCancer 2020 — Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall
• Zhou et al. LungCancer 2020 — Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung
• Floch et al. MolCancerTher 2020 — Osimertinib exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X…
• Ramalingam et al. NEnglJMed 2020 — Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
• Wu et al. NEnglJMed 2020 — Osimertinib in resected EGFR-mutated non-small-cell lung cancer
• Sugiyama et al. SciImmunol 2020 — Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer
• Hastings et al. AnnOncol 2019 — EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
• Leonetti et al. BrJCancer 2019 — Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
• Brown et al. ClinCancerRes 2019 — On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner
• Offin et al. ClinCancerRes 2019 — Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
• Ohe et al. JpnJClinOncol 2019 — Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC FLAURA japanese subset
• Nakagawa et al. LancetOncol 2019 — Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY) a
• Reck et al. LancetRespirMed 2019 — Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150) key subgroup analyses of
• Akamatsu et al. LungCancer 2019 — Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients
• Ichihara et al. LungCancer 2019 — Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer
• Schuler et al. LungCancer 2019 — First-line afatinib for advanced EGFRm+ NSCLC analysis of long-term responders in the LUX-lung 3, 6, and 7 trials
• Vad-Nielsen et al. LungCancer 2019 — Cause-and-effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small
• Ikemura et al. ProcNatlAcadSciUSA 2019 — Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer
• Bonomi et al. AnnOncol 2018 — Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
• Guibert et al. AnnOncol 2018 — Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in
• Kunimasa et al. AnnOncol 2018 — Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1
• Ricordel et al. AnnOncol 2018 — Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
• Taniguchi et al. AnnOncol 2018 — Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung
• Westover et al. AnnOncol 2018 — Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
• Yoshida et al. AnnOncol 2018 — Nivolumab in non-small-cell lung cancer with EGFR mutation
• Watanabe et al. AnticancerRes 2018 — Phase I study evaluating the combination of afatinib with carboplatin and pemetrexed after first-line EGFR-TKIs
• Lee et al. CancerCell 2018 — Targeting PKCdelta as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in
• Piotrowska et al. CancerDiscov 2018 — Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET
• Lim et al. CancerTreatRev 2018 — Acquired resistance to EGFR targeted therapy in non-small cell lung cancer mechanisms and therapeutic strategies
• Yang et al. ClinCancerRes 2018 — Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small
• Oizumi et al. ESMOOpen 2018 — Updated survival outcomes of NEJ005TCOG0902 a randomised phase II study of concurrent versus sequential alternating
• Oshima et al. JAMAOncol 2018 — EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer
• Oxnard et al. JAMAOncol 2018 — Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and
• Gong et al. JClinInvest 2018 — TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
• Ramalingam et al. JClinOncol 2018 — Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
• Reungwetwattana et al. JClinOncol 2018 — CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients
• Wu et al. JClinOncol 2018 — CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer data from a randomized
• Garassino et al. JThoracOncol 2018 — Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients results in never-smokers
• Gettinger et al. JThoracOncol 2018 — Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC
• Lisberg et al. JThoracOncol 2018 — A phase II study of pembrolizumab in EGFR-mutant, PD-l1+, tyrosine kinase inhibitor naive patients with advanced NSCLC
• Minari et al. JThoracOncol 2018 — Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib
• Shibahara et al. JThoracOncol 2018 — Intrinsic and extrinsic regulation of PD-L2 expression in oncogene-driven non-small cell lung cancer
• Su et al. JThoracOncol 2018 — Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase
• Uchibori et al. JThoracOncol 2018 — Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment
• Zhong et al. LancetOncol 2018 — Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC
• Baldacci et al. LungCancer 2018 — MET amplification increases the metastatic spread of EGFR-mutated NSCLC
• Soo et al. LungCancer 2018 — Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer current
• Yoneshima et al. LungCancer 2018 — PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
• Soria et al. NEnglJMed 2018 — Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
• Ahluwalia et al. Oncologist 2018 — Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from non-small cell
• Tung et al. Oncotarget 2018 — PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via
• Young et al. ThrombosRes 2018 — Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer A retrospective
• Haratani et al. AnnOncol 2017 — Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on
• Martinez-Marti et al. AnnOncol 2017 — Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung
• Mayo et al. AnnOncol 2017 — de-Las-Casas-Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide tr…
• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Remon et al. AnnOncol 2017 — Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
• Kosaka et al. CancerRes 2017 — Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors
• Nukaga et al. CancerRes 2017 — Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to
• Vaishnavi et al. CancerRes 2017 — EGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinases
• Shi et al. ClinCancerRes 2017 — Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEKERK-dependent
• Wang et al. ClinCancerRes 2017 — Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages
• Yu et al. ClinCancerRes 2017 — A phase I, dose escalation study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth
• Lin et al. EurJCancer 2017 — An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via
• Magnuson et al. JClinOncol 2017 — Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant
• Mok et al. JClinOncol 2017 — Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell
• Yang et al. JClinOncol 2017 — Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer AURA study phase II extension component
• Chaib et al. JNatlCancerInst 2017 — Coactivation of STAT3 and YAP1 pathway in EGFR-mutant NSCLC
• Lee et al. JThoracOncol 2017 — Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung Cancer-A meta-analysis
• Wang et al. JThoracOncol 2017 — Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first-and
• Wu et al. LancetOncol 2017 — Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung
• Ahn et al. LancetRespirMed 2017 — Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM) a phase 1,
• Rosell et al. LancetRespirMed 2017 — Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)
• OKane et al. LungCancer 2017 — Uncommon EGFR mutations in advanced non-small cell lung cancer
• Soo et al. LungCancer 2017 — Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
• Kobayashi et al. MolCancerTher 2017 — Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung
• Watanabe et al. MolCancerTher 2017 — T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in
• Mok et al. NEnglJMed 2017 — Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
• Jacobsen et al. NatCommun 2017 — Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
• Uchibori et al. NatCommun 2017 — Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
• Blakely et al. NatGenet 2017 — Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
• Dong et al. OncoImmunology 2017 — EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade
• Fan et al. SciRep 2017 — Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and
• Brand et al. SciSignal 2017 — RETRACTED the receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
• Kohsaka et al. SciTranslMed 2017 — A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
• Nilsson et al. SciTranslMed 2017 — Stress hormones promote EGFR inhibitor resistance in NSCLC implications for combinations with beta-blockers
• Jia et al. CancerRes 2016 — EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and
• Kobayashi et al. CancerSci 2016 — Not all epidermal growth factor receptor mutations in lung cancer are created equal perspectives for individualized
• Ballard et al. ClinCancerRes 2016 — Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early
• Gainor et al. ClinCancerRes 2016 — EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in NSCLC
• Karlovich et al. ClinCancerRes 2016 — Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of
• Thompson et al. ClinCancerRes 2016 — Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation
• Zhang et al. IntJOncol 2016 — EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6-JAK-STAT3 signaling pathway in EGFR mutat…
• Oxnard et al. JClinOncol 2016 — Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell
• Urata et al. JClinOncol 2016 — Gefitinib vs erlotinib for EGFR mutant NSCLC Phase 3 WJOG5108L
• Goss et al. LancetOncol 2016 — Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2) a multicentre,
• Park et al. LancetOncol 2016 — Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer
• Guernet et al. MolCell 2016 — CRISPR-Barcoding for intratumor genetic heterogeneity modeling and functional analysis of oncogenic driver mutations
• Chabon et al. NatCommun 2016 — Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
• Shiraishi et al. NatCommun 2016 — Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
• Hata et al. NatMed 2016 — Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
• Jia et al. Nature 2016 — Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
• Gao et al. SciSignal 2016 — JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
• Huang et al. ActaPharmSinB 2015 — Mechanisms of resistance to EGFR tyrosine kinase inhibitors
• Planchard et al. AnnOncol 2015 — EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
• Sugawara et al. AnnOncol 2015 — Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously
• Trivedi et al. AnnOncol 2015 — Immune biomarkers of anti-EGFR monoclonal antibody therapy
• Lin et al. BiochemBiophysResCommun 2015 — EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappab
• Soucheray et al. CancerRes 2015 — Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine
• Corte et al. ClinCancerRes 2015 — SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-EGFR in human…
• Kobayashi et al. ClinCancerRes 2015 — EGFR exon 18 mutations in lung cancer molecular predictors of augmented sensitivity to afatinib or neratinib as
• Lara et al. ClinCancerRes 2015 — Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who
• Matikas et al. ClinLungCancer 2015 — Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs
• Johnson et al. JClinOncol 2015 — Phase III study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to
• Kelly et al. JClinOncol 2015 — Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT) A randomized,
• Lee et al. JClinOncol 2015 — Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after
• Chen et al. JThoracOncol 2015 — Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC implication for optional
• Chiu et al. JThoracOncol 2015 — Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with
• Hoffknecht et al. JThoracOncol 2015 — Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase
• Scheffler et al. JThoracOncol 2015 — Spatial tumor heterogeneity in lung cancer with acquired epidermal growth factor receptor-tyrosine kinase inhibitor
• Tseng et al. JThoracOncol 2015 — Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma
• Soria et al. LancetOncol 2015 — Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after
• Tan et al. LancetOncol 2015 — Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
• Yang et al. LancetOncol 2015 — Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6)
• Yang et al. LancetOncol 2015 — Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations a
• Fukuhara et al. LungCancer 2015 — Factors associated with a poor response to gefitinib in the NEJ002 study smoking and the L858R mutation
• Kogo et al. LungCancer 2015 — Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor
• Lee et al. LungCancer 2015 — Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after
• Janne et al. NEnglJMed 2015 — AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
• Sequist et al. NEnglJMed 2015 — Rociletinib in EGFR-mutated non-small-cell lung cancer
• Niederst et al. NatCommun 2015 — RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
• Thress et al. NatMed 2015 — Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
• Azuma et al. AnnOncol 2014 — Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
• Beau-Faller et al. AnnOncol 2014 — Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients a multicentre observational
• Mok et al. AnnOncol 2014 — Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with
• Ono et al. AnnOncol 2014 — Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation
• Yu et al. AnnOncol 2014 — Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical
• Arteaga et al. CancerCell 2014 — ERBB receptors from oncogene discovery to basic science to mechanism-based cancer therapeutics
• Cross et al. CancerDiscov 2014 — AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
• Janjigian et al. CancerDiscov 2014 — Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and
• deBruin et al. CancerDiscov 2014 — Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
• Nakayama et al. CancerRes 2014 — Beta-catenin contributes to lung tumor development induced by EGFR mutations
• Rho et al. CancerRes 2014 — MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because …
• Rolfo et al. CancerTreatRev 2014 — Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
• Bronte et al. CritRevOncolHematol 2014 — Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment
• Tang et al. JCancerResClinOncol 2014 — Different treatment orders achieved similar clinical results a retrospective study for retreatment of epidermal growth
• Kawaguchi et al. JClinOncol 2014 — Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced
• Gao et al. JNatlCancerInst 2014 — Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
• Shin et al. JThoracOncol 2014 — EGFR mutation and brain metastasis in pulmonary adenocarcinomas
• Watanabe et al. JThoracOncol 2014 — Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
• Seto et al. LancetOncol 2014 — Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung
• Wu et al. LancetOncol 2014 — Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung
• Yamaguchi et al. OncolLett 2014 — Acquired resistance L747S mutation in an EGFR TKI naive patients
• Carnio et al. SeminOncol 2014 — Extending survival of stage IV non-small cell lung cancer
• Inoue et al. AnnOncol 2013 — Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for
• Lee et al. AnnOncol 2013 — Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with
• Koyama et al. AnticancerRes 2013 — Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
• Akbay et al. CancerDiscov 2013 — Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
• Walter et al. CancerDiscov 2013 — Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
• Nakagawa et al. CancerRes 2013 — EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
• Byers et al. ClinCancerRes 2013 — An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies axl
• Byun et al. ClinCancerRes 2013 — USP8 is a novel target for overcoming gefitinib resistance in lung cancer
• Yu et al. ClinCancerRes 2013 — Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant
• Sequist et al. JClinOncol 2013 — Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR
• Kobayashi et al. JThoracOncol 2013 — Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
• Rosell et al. Lancet 2013 — Genetics and biomarkers in personalisation of lung cancer treatment
• Meyer et al. SciSignal 2013 — The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative
• Yasuda et al. SciTranslMed 2013 — Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion
• Togashi et al. CancerChemotherPharmacol 2012 — Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
• Ercan et al. CancerDiscov 2012 — Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors
• Takezawa et al. CancerDiscov 2012 — HER2 amplification a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that
• Suda et al. CancerMetastasisRev 2012 — Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor
• Heon et al. ClinCancerRes 2012 — The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced
• Koizumi et al. ClinLungCancer 2012 — Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer
• Han et al. JClinOncol 2012 — First-SIGNAL first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma
• Su et al. JClinOncol 2012 — Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor
• Takeda et al. JpnJClinOncol 2012 — Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC
• Ciuleanu et al. LancetOncol 2012 — Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell
• Lee et al. LancetOncol 2012 — First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL) a
• Miller et al. LancetOncol 2012 — Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib,
• Rosell et al. LancetOncol 2012 — Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR
• Yang et al. LancetOncol 2012 — Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-lung 2) a phase 2
• Zhang et al. LancetOncol 2012 — Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung
• Oh et al. LungCancer 2012 — Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib a
• Yamaguchi et al. LungCancer 2012 — Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy
• Zhang et al. NatGenet 2012 — Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
• Watanabe et al. BMCCancer 2011 — Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited
• Sasaki et al. CancerRes 2011 — A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
• Arcila et al. ClinCancerRes 2011 — Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M
• Oxnard et al. ClinCancerRes 2011 — Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer distinct natural history of patients
• Wu et al. ClinCancerRes 2011 — Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical
• Becker et al. EurJCancer 2011 — Retreatment with erlotinib regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially
• Zhou et al. LancetOncol 2011 — Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell
• Sequist et al. SciTranslMed 2011 — Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
• Turke et al. CancerCell 2010 — Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
• Lemmon et al. Cell 2010 — Cell signaling by receptor tyrosine kinases
• Heon et al. ClinCancerRes 2010 — Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR
• Li et al. CurrDrugTargets 2010 — Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer
• Jackman et al. JClinOncol 2010 — Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in
• Kaira et al. JThoracOncol 2010 — Pulmonary pleomorphic carcinoma a clinicopathological study including EGFR mutation analysis
• Price et al. JThoracOncol 2010 — Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
• Takeda et al. JThoracOncol 2010 — De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients
• Cappuzzo et al. LancetOncol 2010 — Erlotinib as maintenance treatment in advanced non-small-cell lung cancer a multicentre, randomised, placebo-controlled
• Mitsudomi et al. LancetOncol 2010 — Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the
• Tomizawa et al. LungCancer 2010 — Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
• Maemondo et al. NEnglJMed 2010 — Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
• Sim et al. LungCancer 2009 — Erlotinib after gefitinib failure in female never-smoker asian patients with pulmonary adenocarcinoma
• Mok et al. NEnglJMed 2009 — Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
• Rosell et al. NEnglJMed 2009 — Screening for epidermal growth factor receptor mutations in lung cancer
• Lee et al. AnnOncol 2008 — Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib
• Zucali et al. AnnOncol 2008 — Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
• Costa et al. JClinOncol 2008 — Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired
• Sequist et al. JClinOncol 2008 — First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
• Wong et al. JThoracOncol 2008 — Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive asian patients with
• Kim et al. Lancet 2008 — Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST) a randomised phase III trial
• Linardou et al. LancetOncol 2008 — Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents a systematic
• Maheswaran et al. NEnglJMed 2008 — Detection of mutations in EGFR in circulating lung-cancer cells
• Li et al. Oncogene 2008 — BIBW2992, an irreversible EGFRHER2 inhibitor highly effective in preclinical lung cancer models
• Uramoto et al. AnticancerRes 2007 — A new mechanism for primary resistance to gefitinib in lung adenocarcinoma the role of a novel G796A mutation in exon
• Pallis et al. BrJCancer 2007 — ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated
• Yun et al. CancerCell 2007 — Structures of lung cancer-derived EGFR mutants and inhibitor complexes mechanism of activation and insights into
• Yu et al. CancerRes 2007 — Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals
• Pao et al. ClinCancerRes 2007 — Epidermal growth factor receptor mutation testing in lung cancer searching for the ideal method
• Cho et al. JClinOncol 2007 — Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
• Suehisa et al. JClinOncol 2007 — Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of
• Sharma et al. NatRevCancer 2007 — Epidermal growth factor receptor mutations in lung cancer
• Costa et al. PLoSMed 2007 — BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
• Bean et al. ProcNatlAcadSciUSA 2007 — MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to
• Engelman et al. Science 2007 — MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
• Inukai et al. CancerRes 2006 — Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
• Witta et al. CancerRes 2006 — Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer
• Balak et al. ClinCancerRes 2006 — Novel D761Y and common secondary T790M mutation in EGFR-mutant lung adenocarcinoma with acquired resistance
• Kimura et al. ClinCancerRes 2006 — Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in
• Kosaka et al. ClinCancerRes 2006 — Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired
• Riely et al. ClinCancerRes 2006 — Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21
• Zakowski et al. NEnglJMed 2006 — EGFR mutations in small-cell lung cancers in patients who have never smoked
• Thomson et al. CancerRes 2005 — Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and
• Yauch et al. ClinCancerRes 2005 — Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in
• Herbst et al. JClinOncol 2005 — TRIBUTE a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in
• Shigematsu et al. JNatlCancerInst 2005 — Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
• Thatcher et al. Lancet 2005 — Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer
• Kobayashi et al. NEnglJMed 2005 — EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
• Shepherd et al. NEnglJMed 2005 — Erlotinib in previously treated non-small-cell lung cancer
• Shih et al. NEnglJMed 2005 — EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer
• Bell et al. NatGenet 2005 — Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
• Pao et al. PLoSMed 2005 — Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR
• Pao et al. PLoSMed 2005 — KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
• Kwak et al. ProcNatlAcadSciUSA 2005 — Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
• Kosaka et al. CancerRes 2004 — Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications
• Giaccone et al. JClinOncol 2004 — Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer a phase III trial-INTACT
• Lynch et al. NEnglJMed 2004 — Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to
• Pao et al. ProcNatlAcadSciUSA 2004 — EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors
• Paez et al. Science 2004 — EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy
• Sordella et al. Science 2004 — Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
• Kris et al. JAMA 2003 — Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients
• Fukuoka et al. JClinOncol 2003 — Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell
• yarden et al. NatRevMolCellBiol 2001 — Untangling the ErbB signalling network

Clinical-NSCLC-HER2

• Ruan et al. AnnOncol 2026 — Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate,
• Tillman et al. CancerCell 2026 — Reimagining HER2 therapy bridging oncogene addiction and immune modulation
• Shitara et al. NEnglJMed 2026 — Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer
• Terao et al. NPJBreastCancer 2026 — Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response
• Smit et al. LancetOncol 2024 — Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (destiny-lung01) primary results of the
• Goto et al. JClinOncol 2023 — Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer primary results from the
• Yu et al. JClinOncol 2023 — HERTHENA-lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated
• Li et al. NEnglJMed 2022 — Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
• Friedlaender et al. NatRevClinOncol 2022 — EGFR and HER2 exon 20 insertions in solid tumours from biology to treatment
• Han et al. CancerRes 2021 — Targeting HER2 exon 20 insertion-mutant lung adenocarcinoma with a novel tyrosine kinase inhibitor mobocertinib
• Zhao et al. JThoracOncol 2020 — Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung
• Wang et al. AnnOncol 2019 — HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine
• Peters et al. ClinCancerRes 2019 — Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung
• Goss et al. JAMAOncol 2018 — Association of ERBB mutations with clinical outcomes of afatinib-or erlotinib-treated patients with lung squamous cell
• Hyman et al. Nature 2018 — HER kinase inhibition in patients with HER2-and HER3-mutant cancers
• Kris et al. AnnOncol 2015 — Targeting HER2 aberrations as actionable drivers in lung cancers phase II trial of the pan-HER tyrosine kinase
• Stephens et al. Nature 2004 — Lung cancer intragenic ERBB2 kinase mutations in tumours

Clinical-NSCLC-ROS1

• Ma et al. CancerCell 2026 — JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC
• Itchins et al. LungCancer 2026 — Real-world treatment sequencing and survival in ROS1-rearranged NSCLC across evolving treatment eras findings from the
• Drilon et al. NEnglJMed 2024 — Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer
• Lin et al. ClinCancerRes 2021 — Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer
• Almquist et al. JCOOncolPract 2021 — The road less traveled A guide to metastatic ROS1-rearranged non-small-cell lung cancer
• Dziadziuszko et al. JClinOncol 2021 — Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1
• Ou et al. JTOClinResRep 2021 — Efficacy of taletrectinib (AB-106ds-6051b) in ROS1+ NSCLC an updated pooled analysis of U.S. and japan phase 1 studies
• Parrott et al. AAPSJ 2020 — Physiologically based absorption modelling to explore the impact of food and gastric pH changes on the pharmacokinetics
• DAngelo et al. Cancers 2020 — Focus on ROS1-positive non-small cell lung cancer (NSCLC) crizotinib, resistance mechanisms and the newer generation of
• Papadopoulos et al. ClinCancerRes 2020 — U.S. phase I first-in-human study of taletrectinib (DS-6051bab-106), a ROS1TRK inhibitor, in patients with advanced
• Yun et al. ClinCancerRes 2020 — Repotrectinib exhibits potent antitumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small
• Ku et al. InvestNewDrugs 2020 — Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
• Mezquita et al. JCOPrecisOncol 2020 — Clinical relevance of an amplicon-based liquid biopsy for detecting ALK and ROS1 fusion and resistance mutations in
• Zhu et al. JThoracOncol 2020 — An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs
• Drilon et al. LancetOncol 2020 — Entrectinib in ROS1 fusion-positive non-small-cell lung cancer integrated analysis of three phase 1-2 trials
• Moro et al. AnnOncol 2019 — Sibilot-Crizotinib in c-MET-or ROS1-positive NSCLC results of the AcSe phase II trial
• Shaw et al. AnnOncol 2019 — Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC) updated results, including overall survival,
• Roys et al. CancerChemotherPharmacol 2019 — Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
• Neel et al. CancerRes 2019 — Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins
• Landi et al. ClinCancerRes 2019 — Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS) A phase II,
• Yu et al. ClinLungCancer 2019 — Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of
• Hofman et al. JThoracOncol 2019 — Multicenter evaluation of a novel ROS1 IHC assay SP384 for detection of ROS1 rearragements in a large cohort of lung …
• Michels et al. JThoracOncol 2019 — Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS) A
• Sun et al. JThoracOncol 2019 — Tumor heterogeneity and testing discrepancy confound ROS1 detection in NSCLC
• Shaw et al. LancetOncol 2019 — Lorlatinib in advanced ROS1-positive non-small-cell lung cancer a multicentre, open-label, single-arm, phase 1-2 trial
• Ou et al. LungCancer 2019 — CNS metastasis in ROS1+ NSCLC an urgent call to action, to understand, and to overcome
• Katayama et al. NatCommun 2019 — The new-generation selective ROS1NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in
• Wu et al. JClinOncol 2018 — Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer
• Li et al. JThoracOncol 2018 — Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small cell
• Park et al. JThoracOncol 2018 — Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice
• Patil et al. JThoracOncol 2018 — The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous
• Solomon et al. LancetOncol 2018 — Lorlatinib in patients with ALK-positive non-small-cell lung cancer results from a global phase 2 study
• Fujiwara et al. Oncotarget 2018 — Safety and pharmacokinetics of DS-6051b in japanese patients with non-small cell lung cancer harboring ROS1 fusions a
• Drilon et al. CancerDiscov 2017 — Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib combined results from
• Gainor et al. JCOPrecisOncol 2017 — Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer
• Lim et al. JClinOncol 2017 — Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1
• Pal et al. JClinPathol 2017 — ROS1 corrected
• Lin et al. JThoracOncol 2017 — Recent advances in targeting ROS1 in lung cancer
• Zhao et al. OncoTargetsTher 2017 — Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
• Ogura et al. SciRep 2017 — TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
• Facchinetti et al. ClinCancerRes 2016 — Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1-and ALK-rearranged
• Ardini et al. MolCancerTher 2016 — Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications
• Song et al. ClinCancerRes 2015 — Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer
• Mazieres et al. JClinOncol 2015 — Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement results from the EUROS1 cohort
• Zou et al. ProcNatlAcadSciUSA 2015 — PF-06463922 is a potent and selective next-generation ROS1ALK inhibitor capable of blocking crizotinib-resistant ROS1
• Shaw et al. NEnglJMed 2014 — Crizotinib in ROS1-rearranged non-small-cell lung cancer
• Kim et al. AnnOncol 2013 — The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
• Davies et al. ClinCancerRes 2013 — Molecular pathways ROS1 fusion proteins in cancer
• Awad et al. NEnglJMed 2013 — Acquired resistance to crizotinib from a mutation in CD74-ROS1
• Gainor et al. Oncologist 2013 — Novel targets in non-small cell lung cancer ROS1 and RET fusions
• Davies et al. ClinCancerRes 2012 — Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
• Bergethon et al. JClinOncol 2012 — ROS1 rearrangements define a unique molecular class of lung cancers
• Janne et al. JClinOncol 2012 — ROS1 rearrangements in lung cancer a new genomic subset of lung adenocarcinoma
• Komiya et al. JClinOncol 2012 — Response to crizotinib in ROS1-rearranged non-small-cell lung cancer
• Chin et al. JThoracOncol 2012 — Targeting ROS1 with anaplastic lymphoma kinase inhibitors a promising therapeutic strategy for a newly defined

Clinical-SCLC

• Sethakorn et al. Cancer 2026 — The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer
• Campisi et al. CancerCell 2026 — Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
• Hao et al. CancerCommun(Lond) 2026 — Serplulimab plus chemotherapy, with or without HLX04, versus chemotherapy as first-line treatment for nonsquamous NSCLC
• Trotta et al. Cell 2026 — Excessive vascular integrity restricts anti-tumor immunity
• Wang et al. CellRepMed 2026 — Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined
• Guan et al. CritRevOncolHematol 2026 — Overcoming immunotherapy resistance in extensive-stage small cell lung cancer insights into mechanisms and therapeutic
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and
• Zhang et al. FrontImmunol 2026 — First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain
• Liu et al. FrontPharmacol 2026 — Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based
• Liu et al. JAMAOncol 2026 — First-line serplulimab in extensive-stage small cell lung cancer secondary analysis of the ASTRUM-005 phase 3
• Byers et al. NatMed 2026 — SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors a phase 1 trial
• Sun et al. Oncologist 2026 — Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-beta in patients with advanced solid tumors
• Zhao et al. SignalTransductTargetTher 2026 — Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01) a
• Rekhtman et al. CancerDiscov 2025 — Chromothripsis-mediated small cell lung carcinoma
• Li et al. JCOGlobOncol 2025 — Durvalumab in limited-stage small cell lung cancer clinical triumph and toward sustainable value
• Miyauchi et al. JTOClinResRep 2025 — J-TAIL-2 A prospective, observational study of atezolizumab combined with carboplatin and etoposide in patients with
• Paz-Ares et al. Lancet 2025 — Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage
• Paulson et al. LancetOncol 2025 — Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after
• Asao et al. LancetRespirMed 2025 — Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer
• Reguart et al. LancetRespirMed 2025 — Rethinking immunotherapy in patients with SCLC with poor performance status
• Mountzios et al. NEnglJMed 2025 — Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
• Duplaquet et al. CancerCell 2024 — Mammalian swisnf complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer
• Choi et al. CancerResTreat 2024 — The real-world outcome of first line atezolizumab in extensive-stage small cell lung cancer A multicenter prospective
• Liu et al. Cell 2024 — Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeu…
• Falchero et al. EurJCancer 2024 — Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years impact of
• Cheng et al. NEnglJMed 2024 — Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
• Doshita et al. AdvRadiatOncol 2023 — Incidence and treatment outcome of radiation pneumonitis in patients with limited-stage small cell lung cancer treated
• Agarwal et al. Cancer 2023 — Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status
• Lee et al. CancerResTreat 2023 — A randomized phase II study of irinotecan plus cisplatin with or without simvastatin in ever-smokers with extended
• Khurshid et al. JClinOncol 2023 — Systemic therapy for small-cell lung cancer ASCO-ontario health (cancer care ontario) guideline
• Mamesaya et al. ThoracCancer 2023 — Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor
• Asao et al. BMCCancer 2022 — A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung
• Rittberg et al. FrontOncol 2022 — Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
• Li et al. IntJRadiatOncolBiolPhys 2022 — Comprehensive next-generation sequencing reveals novel predictive biomarkers of recurrence and thoracic toxicity risks
• Redin et al. JThoracOncol 2022 — YES1 is a druggable oncogenic target in SCLC
• Sagie et al. LungCancer 2022 — Real-world evidence for immunotherapy in the first line setting in small cell lung cancer
• Chemi et al. NatCancer 2022 — CfDNA methylome profiling for detection and subtyping of small cell lung cancers
• Dingemans et al. AnnOncol 2021 — Small-cell lung cancer ESMO clinical practice guidelines for diagnosis, treatment and follow-up
• Spigel et al. AnnOncol 2021 — Second-line nivolumab in relapsed small-cell lung cancer CheckMate 331
• Jones et al. AnnPalliatMed 2021 — Factors associated with survival in small cell lung cancer an analysis of real-world national audit, chemotherapy and
• Ohara et al. BiochemBiophysRep 2021 — SCLC-J1 a novel small cell lung cancer cell line
• Chan et al. CancerCell 2021 — Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
• Frese et al. CancerCell 2021 — Small cell lung cancer enters the era of precision medicine
• Gay et al. CancerCell 2021 — Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with disti…
• Schaff et al. CancerRes 2021 — Fragmentation of small-cell lung cancer regulatory states in heterotypic microenvironments
• Zhu et al. CancerRes 2021 — Evasion of innate immunity contributes to small cell lung cancer progression and metastasis
• Giffin et al. ClinCancerRes 2021 — AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in
• Weiss et al. ClinLungCancer 2021 — Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with
• Daniel et al. IntJCancer 2021 — Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung
• Liu et al. JClinOncol 2021 — Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated
• Owonikoko et al. JClinOncol 2021 — Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer CheckMate 451
• Rodriguez et al. JClinOncol 2021 — Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell
• Elegbede et al. JTOClinResRep 2021 — A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in
• Malhotra et al. JThoracOncol 2021 — A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with
• Owonikoko et al. JThoracOncol 2021 — YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype
• Goldman et al. LancetOncol 2021 — Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line
• Rudin et al. NatRevDisPrimers 2021 — Small-cell lung cancer
• Noronha et al. ActaOncol 2020 — The role of chemotherapy in patients with small cell lung cancer and poor performance status
• Mansfield et al. AnnOncol 2020 — Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung
• Zhang et al. CancerCell 2020 — CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer
• Tlemsani et al. CellRep 2020 — SCLC-CellMiner A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures
• Friedlaender et al. ClinLungCancer 2020 — The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors
• Rittberg et al. ClinLungCancer 2020 — Effect of hospitalization during first chemotherapy and performance status on small-cell lung cancer outcomes
• Rudin et al. JClinOncol 2020 — Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer
• Lai et al. JImmunotherCancer 2020 — CDK46 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in
• Baine et al. JThoracOncol 2020 — SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1 A comprehensive immunohistochemical and histopathologic
• Chung et al. JThoracOncol 2020 — Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC results from
• Ready et al. JThoracOncol 2020 — Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer results from the CheckMate 032
• Welsh et al. JThoracOncol 2020 — Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung
• Baize et al. LancetOncol 2020 — Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed SCLC
• Trigo et al. LancetOncol 2020 — Lurbinectedin as second-line treatment for patients with small-cell lung cancer a single-arm, open-label, phase 2
• Subbiah et al. LungCancer 2020 — Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge
• Simpson et al. NatCancer 2020 — A biobank of small cell lung cancer CDX models elucidates inter-and intratumoral phenotypic heterogeneity
• Iams et al. NatRevClinOncol 2020 — Immunotherapeutic approaches for small-cell lung cancer
• Bahij et al. ActaOncol 2019 — Outcome of treatment in patients with small cell lung cancer in poor performance status
• Tay et al. AnnOncol 2019 — Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer analysis of the concurrent
• Weiss et al. AnnOncol 2019 — Myelopreservation with the CDK46 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line
• Hiatt et al. CancerDiscov 2019 — Delivering a STINGing blow to small cell lung cancer via synergistic inhibition of DNA-damage response and
• Sen et al. CancerDiscov 2019 — Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung
• Aida et al. CaseRepOncol 2019 — Small-cell lung cancer treatment of newly diagnosed patients with poor performance status
• Atrafi et al. ClinCancerRes 2019 — A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage
• Morgensztern et al. ClinCancerRes 2019 — Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing,
• Su et al. ClinCancerRes 2019 — Inferring the evolution and progression of small-cell lung cancer by single-cell sequencing of circulating tumor cells
• Tian et al. JHematolOncol 2019 — Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small
• Ricciuti et al. JImmunotherCancer 2019 — Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint
• Muppa et al. JThoracOncol 2019 — Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer
• Park et al. JThoracOncol 2019 — DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based c…
• Ready et al. JThoracOncol 2019 — Third-line nivolumab monotherapy in recurrent SCLC CheckMate 032
• Paz-Ares et al. Lancet 2019 — Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung
• Kim et al. LungCancer 2019 — A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
• Lattuca-Truc et al. LungCancer 2019 — Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017
• Rudin et al. NatRevCancer 2019 — Molecular subtypes of small cell lung cancer a synthesis of human and mouse model data
• Yamaguchi et al. AnnCancerResTher 2018 — Clinical benefit of chemotherapy for SCLC patients with extremely poor performance status
• Hellmann et al. CancerCell 2018 — Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung
• Yang et al. CancerDiscov 2018 — Intertumoral heterogeneity in SCLC is influenced by the cell type of origin
• Meder et al. CancerRes 2018 — Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell
• Bonanno et al. EurJCancer 2018 — The role of immune microenvironment in small-cell lung cancer distribution of PD-L1 expression and prognostic role of
• Araujo et al. JThoracOncol 2018 — Treatment of patients with poor performance status (ECOG3-4)
• Gadgeel et al. JThoracOncol 2018 — Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)
• Kim et al. JThoracOncol 2018 — Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine
• Horn et al. NEnglJMed 2018 — First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
• Igawa et al. Oncology 2018 — Efficacy of platinum-based chemotherapy for relapsed small-cell lung cancer after amrubicin monotherapy in elderly
• Igawa et al. ThoracCancer 2018 — Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the
• Zhang et al. TranslLungCancerRes 2018 — Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
• George et al. ClinCancerRes 2017 — Genomic amplification of CD274 (PD-L1) in small-cell lung cancer
• Gray et al. ClinCancerRes 2017 — Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting
• Okuma et al. ClinLungCancer 2017 — Comparison of amrubicin and weekly CisplatinEtoposideIrinotecan in patients with relapsed small-cell lung cancer
• Igawa et al. InvestNewDrugs 2017 — Phase II study of amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung
• Jalal et al. JClinOncol 2017 — Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer A
• Ott et al. JClinOncol 2017 — Pembrolizumab in patients with extensive-stage small-cell lung cancer results from the phase ib KEYNOTE-028 study
• Tiseo et al. JClinOncol 2017 — Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line
• Takahashi et al. LancetOncol 2017 — Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer a
• Tsuruoka et al. LungCancer 2017 — PD-L1 expression in neuroendocrine tumors of the lung
• Carter et al. NatMed 2017 — Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive
• Sabari et al. NatRevClinOncol 2017 — Unravelling the biology of SCLC implications for therapy
• Oh et al. BMCCancer 2016 — Belotecancisplatin versus etoposidecisplatin in previously untreated patients with extensive-stage small cell lung
• Borromeo et al. CellRep 2016 — ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs
• Reck et al. JClinOncol 2016 — Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in
• Arriola et al. JThoracOncol 2016 — Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and
• Antonia et al. LancetOncol 2016 — Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032) a multicentre,
• Goto et al. LancetOncol 2016 — Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for
• Minami et al. LungCancer(Auckl) 2016 — Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
• Yamane et al. AmJCancerRes 2015 — Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung
• Leighl et al. JClinOncol 2015 — Sunitinib the next advance in small-cell lung cancer
• Ishii et al. JThoracOncol 2015 — Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell
• Asao et al. JpnJClinOncol 2015 — Phase II study of amrubicin at a dose of 45 mgm2 in patients with previously treated small-cell lung cancer
• Slotman et al. Lancet 2015 — Use of thoracic radiotherapy for extensive stage small-cell lung cancer a phase 3 randomised controlled trial
• George et al. Nature 2015 — Comprehensive genomic profiles of small cell lung cancer
• Poirier et al. Oncogene 2015 — DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
• Saunders et al. SciTranslMed 2015 — A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
• Amini et al. Cancer 2014 — Progress in the management of LD-SCLC
• Ikeda et al. CancerChemotherPharmacol 2014 — A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung
• Satouchi et al. JClinOncol 2014 — Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease
• vonPawel et al. JClinOncol 2014 — Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung
• Harada et al. JpnJClinOncol 2014 — A phase III trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer
• Kubota et al. LancetOncol 2014 — Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated
• Murakami et al. LungCancer 2014 — A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer japan clinical
• Wakuda et al. LungCancer 2014 — Molecular profiling of small cell lung cancer in a japanese cohort
• Pillai et al. SeminOncol 2014 — Small cell lung cancer therapies and targets
• Reck et al. AnnOncol 2013 — Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung
• Pelayo et al. CochraneDatabaseSystRev 2013 — Chemotherapy versus best supportive care for ED-SCLC
• Montella et al. JClinOncol 2013 — Evaluation of elderly patients with extended disease small-cell lung cancer
• Isobe et al. JThoracOncol 2013 — Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer
• Hong et al. CancerChemotherPharmacol 2012 — Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of
• Rossi et al. JClinOncol 2012 — Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer the COCIS meta-analysis
• Fink et al. JThoracOncol 2012 — Topotecancisplatin compared with cisplatinetoposide as first-line treatment for patients with extensive disease
• Owonikoko et al. JThoracOncol 2012 — A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer
• Rudin et al. NatGenet 2012 — Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
• Baldotto et al. SupportCareCancer 2012 — Palliative care in poor-performance status small cell lung cancer patients is there a mandatory role for chemotherapy
• Jotte et al. JClinOncol 2011 — Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell
• vanMeerbeeck et al. Lancet 2011 — Small-cell lung cancer
• Ettinger et al. JClinOncol 2010 — Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer
• Jiang et al. JThoracOncol 2010 — A meta-analysis of randomized controlled trials comparing irinotecanplatinum with etoposideplatinum in patients with
• Lima et al. JThoracOncol 2010 — Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer
• Noguchi et al. JThoracOncol 2010 — A retrospective analysis of clinical outcomes of patients older than or equal to 80 years with small cell lung cancer
• Pleasance et al. Nature 2010 — A small-cell lung cancer genome with complex signatures of tobacco exposure
• Foster et al. Cancer 2009 — Prognostic factors differ by tumor stage for small cell lung cancer a pooled analysis of north central cancer treatment
• Koletsis et al. JCardiothoracSurg 2009 — Current role of surgery in small cell lung carcinoma
• Horn et al. JClinOncol 2009 — Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung
• Lara et al. JClinOncol 2009 — Phase III trial of irinotecancisplatin compared with etoposidecisplatin in extensive-stage small-cell lung cancer
• Socinski et al. JClinOncol 2009 — Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients
• Koyama et al. ClinCancerRes 2008 — Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung
• Hermes et al. JClinOncol 2008 — Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer a randomized
• Inoue et al. JClinOncol 2008 — Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer
• Kenmotsu et al. JClinOncol 2008 — Clinical significance of chemotherapy for small cell lung cancer (SCLC) with ECOG performance status (PS) 3-4
• Sculier et al. JThoracOncol 2008 — The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease
• Kim et al. LungCancer 2008 — Combination chemotherapy with irinotecan and cisplatin in elderly patients with extensive-stage small-cell lung cancer
• Okamoto et al. BrJCancer 2007 — Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or
• Pijls-Johannesma et al. CancerTreatRev 2007 — Timing of chest radiotherapy in patients with limited stage small cell lung cancer a systematic review and
• Sculier et al. EurRespirJ 2007 — Chemotherapy improves low performance status lung cancer patients
• Yana et al. InvestNewDrugs 2007 — Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer west japan
• Eckardt et al. JClinOncol 2007 — Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
• Shepherd et al. JThoracOncol 2007 — The international association for the study of lung cancer lung cancer staging project proposals regarding the clinical
• Slotman et al. NEnglJMed 2007 — Prophylactic cranial irradiation in extensive small-cell lung cancer
• Okamoto et al. AnnOncol 2006 — EGFR mutation in gefitinib-responsive small-cell lung cancer
• Cronenberger et al. JClinOncol 2006 — Role of chemotherapy (CT) in performance status 3 and 4 small cell lung cancer (SCLC) patients
• Eckardt et al. JClinOncol 2006 — Open-label, multicenter, randomized, phase III study comparing oral topotecancisplatin versus etoposidecisplatin as
• Hanna et al. JClinOncol 2006 — Randomized phase III trial comparing irinotecancisplatin with etoposidecisplatin in patients with previously untreated
• OBrien et al. JClinOncol 2006 — Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed
• Onoda et al. JClinOncol 2006 — Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer thoracic oncology research
• Spiro et al. JClinOncol 2006 — Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer a
• Sohn et al. LungCancer 2006 — A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung
• Anraku et al. SeminThoracCardiovascSurg 2006 — Surgery for small-cell lung cancer
• Ohe et al. AnnOncol 2005 — Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
• Tsuchiya et al. JThoracCardiovascSurg 2005 — Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa
• Han et al. MedOncol 2005 — A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive
• Frasci et al. Oncology 2005 — Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support
• Hainsworth et al. Cancer 2004 — Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and
• Neubauer et al. JClinOncol 2004 — Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer
• Mackay et al. ClinOncol(RCollRadiol) 2003 — A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer
• Weinmann et al. LungCancer 2003 — Treatment of lung cancer in elderly part II small cell lung cancer
• Hanna et al. AnnOncol 2002 — Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus
• Noda et al. NEnglJMed 2002 — Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
• Frasci et al. BrJCancer 2001 — A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients
• Sambrook et al. BrJCancer 2001 — A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the united kingdom
• Sculier et al. BrJCancer 2001 — A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer,
• Kelly et al. ClinCancerRes 2001 — Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with
• Schiller et al. JClinOncol 2001 — Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer E7593-a phase III
• Pujol et al. JNatlCancerInst 2001 — Etoposide plus cisplatin with or without the combination of 4’-epidoxorubicin plus cyclophosphamide in treatment of
• Paesmans et al. Cancer 2000 — Prognostic factors for patients with small cell lung carcinoma analysis of a series of 763 patients included in 4
• Eerola et al. ClinCancerRes 2000 — A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a
• Lassen et al. BrJCancer 1999 — Early death during chemotherapy in patients with small-cell lung cancer derivation of a prognostic index for toxic
• Bonner et al. JClinOncol 1999 — Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited
• Okamoto et al. JClinOncol 1999 — Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose
• vonPawel et al. JClinOncol 1999 — Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
• Turrisi et al. NEnglJMed 1999 — Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with
• Rea et al. EurJCardiothoracSurg 1998 — Long term results of surgery and chemotherapy in small cell lung cancer
• Westeel et al. JClinOncol 1998 — New combination of the old drugs for elderly patients with small-cell lung cancer a phase II study of the PAVE regimen
• Maestu et al. AnnOncol 1997 — Pretreatment prognostic factors for survival in small-cell lung cancer a new prognostic index and validation of three
• Gregor et al. JClinOncol 1997 — Randomized trial of alternating versus sequential radiotherapychemotherapy in limited-disease patients with small-cell
• Kawahara et al. JpnJClinOncol 1997 — Prognostic factors and prognostic staging system for small cell lung cancer
• Sakuragi et al. JpnJClinOncol 1996 — Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status
• Girling et al. Lancet 1996 — Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer a stopped
• Lassen et al. JClinOncol 1995 — Long-term survival in small-cell lung cancer posttreatment characteristics in patients surviving 5 to 18+ years-an
• Lad et al. Chest 1994 — A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of
• Livingston et al. Cancer 1993 — Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study
• Murray et al. JClinOncol 1993 — Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung
• Kudoh et al. AmJClinOncol 1992 — Weekly dose-intensive chemotherapy in patients with small-cell lung cancer a pilot study
• Roth et al. JClinOncol 1992 — Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of
• Warde et al. JClinOncol 1992 — Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung A
• Pignon et al. NEnglJMed 1992 — A meta-analysis of thoracic radiotherapy for small-cell lung cancer
• Wolf et al. BrJCancer 1991 — Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC) the role of sex as a predictor for
• Jett et al. JClinOncol 1990 — Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without
• Shepherd et al. JClinOncol 1988 — Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung
• Smith et al. JClinOncol 1987 — Carboplatin (paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer
• Friess et al. JClinOncol 1985 — Effect of initial resection of small-cell carcinoma of the lung a review of southwest oncology group study 7628
• Lancet 1966 — Comparetive trial of surgery and radiotherapy for SCLC

Clinical-Supportive care

• Prescott et al. IntensiveCareMed 2026 — Surviving sepsis campaign international guidelines for management of sepsis and septic shock 2026
• Lin et al. TranslLungCancerRes 2026 — International consensus on severe lung cancer the second edition
• Tanaka et al. Diagnostics 2022 — Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of
• Koyanagi et al. CancerRes 2021 — Pronociceptive roles of schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy
• Arends et al. ESMOOpen 2021 — Cancer cachexia in adult patients ESMO clinical practice guidelines
• Griggs et al. JClinOncol 2021 — Appropriate systemic therapy dosing for obese adult patients with cancer ASCO guideline update
• Blayney et al. JAMAOncol 2020 — Efficacy of plinabulin vs pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults with non-small
• Roeland et al. JClinOncol 2020 — Management of cancer cachexia ASCO guideline
• Scott et al. JClinOncol 2020 — Performance status in cancer not broken, but time for an upgrade
• Katakami et al. Cancer 2018 — Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia results from a
• Turner et al. ClinCancerRes 2018 — Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
• Horinouchi et al. ESMOOpen 2018 — Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients
• Hata et al. Oncotarget 2018 — Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated
• Takayama et al. SupportCareCancer 2016 — Anamorelin (ONO-7643) in japanese patients with non-small cell lung cancer and cachexia results of a randomized phase 2
• Takayama et al. SupportCareCancer 2016 — Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-japan nutrition
• Watkins et al. CancerControl 2015 — Transfusion indications for patients with cancer
• vonHaehling et al. JCachexiaSarcopeniaMuscle 2014 — Prevalence, incidence and clinical impact of cachexia facts and numbers-update 2014
• Gajra et al. JNatlComprCancNetw 2014 — Management of patients with lung cancer and poor performance status
• Argiles et al. NatRevCancer 2014 — Cancer cachexia Understanding the molecular basis
• Park et al. AnnOncol 2013 — Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung
• Brunelli et al. Chest 2013 — Physiologic evaluation of the patient with lung cancer being considered for resectional surgery diagnosis and
• Ito et al. InternMed 2013 — Acute aortic thrombosis during cisplatin based chemotherapy for gastric cancer
• Smith et al. JAMA 2013 — Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral
• McCurdy et al. CritCareMed 2012 — Oncologic emergencies
• Loblaw et al. IntJRadiatOncolBiolPhys 2012 — A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord
• Hahn et al. IntJClinOncol 2011 — A case of acute aortic thrombosis after cisplatin-based chemotherapy
• Sun et al. HematolOncolClinNorthAm 2010 — Optimal management of malignant epidural spinal cord compression
• Pelosof et al. MayoClinProc 2010 — Paraneoplastic syndromes an approach to diagnosis and treatment
• Yu et al. JThoracOncol 2008 — Superior vena cava syndrome-a proposed classification system and algorithm for management
• Cole et al. LancetNeurol 2008 — Metastatic epidural spinal cord compression
• Teunissen et al. JPainSymptomManage 2007 — Symptom prevalence in patients with incurable cancer a systematic review
• Lenz et al. Oncologist 2007 — Management and preparedness for infusion and hypersensitivity reactions
• Aaronson et al. JNatlCancerInst 1993 — The EORTC QLQ-C30 a quality-of-life instrument for use in international clinical trials in oncology
• Bach et al. JClinOncol 1992 — Metastatic spinal cord compression secondary to lung cancer
• Karnofsky et al. Cancer 1948 — The use of the nitrogen mustards in the palliative treatment of carcinoma

Clinical-Thymic

• Imbimbo et al. ESMORareCancers 2025 — Thymic epithelial tumors What’s newa and what’s next
• Masui et al. ExpertRevAnticancerTher 2025 — An update on the therapeutic options for metastatic thymomas and thymic carcinomas
• Riely et al. JNatlComprCancNetw 2025 — Thymomas and thymic carcinomas, version 2.2025, NCCN clinical practice guidelines in oncology
• Shukuya et al. LancetOncol 2025 — Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic
• Mohrmann et al. Med 2025 — Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors
• Proto et al. AnnOncol 2024 — Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma RELEVENT
• Rajan et al. Cancers 2024 — Immunotherapy for thymomas and thymic carcinomas Current status and future directions
• Ardeshir-Larijani et al. ClinLungCancer 2024 — Trop-2 expression and its impact on survival in thymic epithelial tumors brief report
• Perrino et al. FrontImmunol 2024 — Autoimmunity in thymic epithelial tumors a not yet clarified pathologic paradigm associated with several unmet clinical
• Nabel et al. Oncologist 2024 — Single-cell sequencing illuminates thymic development an updated framework for understanding thymic epithelial tumors
• Asao et al. ClinLungCancer 2023 — Study design and rationale for marble study A phase II trial of atezolizumab (MPDL3280A) plus carboplatin and
• Girard et al. ESMOOpen 2023 — Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma results from the
• Ruffini et al. JThoracOncol 2023 — The international association for the study of lung cancer thymic epithelial tumors staging project proposal for a
• Yeung et al. LungCancer 2023 — High levels of expression of Trop-2 in thymic epithelial tumors
• Li et al. SeminImmunol 2023 — Thymus aging and immune reconstitution, progresses and challenges
• Caruso et al. TrendsCancer 2023 — Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies
• Bocchialini et al. BrJCancer 2022 — Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome
• Katsuya et al. FrontOncol 2022 — Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
• Marx et al. JThoracOncol 2022 — The 2021 WHO classification of tumors of the thymus and mediastinum what is new in thymic epithelial, germ cell, and
• Conforti et al. LancetOncol 2022 — Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT) a single-arm,
• Xin et al. NatCommun 2022 — The immune landscape of human thymic epithelial tumors
• Yasumizu et al. NatCommun 2022 — Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma
• Prays et al. SeminDiagnPathol 2022 — Molecular landscape of thymic epithelial tumors
• Kaira et al. Cancers 2021 — Perspective of immune checkpoint inhibitors in thymic carcinoma
• He et al. CellRepMed 2021 — Molecular predictors of response to pembrolizumab in thymic carcinoma
• Giaccone et al. JThoracOncol 2021 — Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up
• Rajan et al. JThoracOncol 2021 — Immunotherapy for thymic cancers A convoluted path toward a cherished goal
• Yamada et al. JThoracOncol 2021 — A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets
• Okuma et al. CancerMed 2020 — Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
• Sato et al. LancetOncol 2020 — Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA) a multicentre, phase 2 trial
• Alvarez-Quilon et al. NatCommun 2020 — Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency
• Tateishi et al. Oncologist 2020 — Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma A
• Kim et al. ClinCancerRes 2019 — The first-week proliferative response of peripheral blood PD-1+cd8+ T cells predicts the response to anti-PD-1 therapy
• Katsuya et al. EurJCancer 2019 — Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma PRIMER study
• Cho et al. JClinOncol 2019 — Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor an open-label phase II trial
• Rajan et al. JImmunotherCancer 2019 — Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma
• Hsu et al. PLoSONE 2019 — Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States
• Thapa et al. ThoracSurgClin 2019 — The role of the thymus in the immune response
• Radovich et al. CancerCell 2018 — The integrated genomic landscape of thymic epithelial tumors
• Napieralska et al. JThoracDis 2018 — Primary mediastinal seminoma
• Giaccone et al. LancetOncol 2018 — Pembrolizumab in patients with thymic carcinoma a single-arm, single-centre, phase 2 study
• Ko et al. Oncologist 2018 — Prognostic factors and efficacy of first-line chemotherapy in patients with advanced thymic carcinoma A retrospective
• Conforti et al. CancerRes 2017 — Therapeutic effects of XPO1 inhibition in thymic epithelial tumors
• Saito et al. Carcinogenesis 2017 — The genomic and epigenomic landscape in thymic carcinoma
• Lee et al. ClinCancerRes 2017 — Genomic analysis of thymic epithelial tumors identifies novel subtypes associated with distinct clinical features
• Yokoyama et al. ClinCancerRes 2016 — Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma
• Asao et al. LungCancer 2016 — Medical treatment involving investigational drugs and genetic profile of thymic carcinoma
• Hirai et al. AnnOncol 2015 — A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma WJOG4207L
• Serpico et al. AnnOncol 2015 — Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
• Omasa et al. Cancer 2015 — Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial
• Ahmad et al. JThoracCardiovascSurg 2015 — Thymic carcinoma outcomes and prognosis Results of an international analysis
• Moreira et al. JThoracOncol 2015 — Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis
• Padda et al. JThoracOncol 2015 — Diffuse high intensity PD-L1 staining in thymic epithelial tumors
• Weis et al. JThoracOncol 2015 — The impact of thymoma histotype on prognosis in a worldwide database
• Thomas et al. LancetOncol 2015 — Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma an open-label phase 2 trial
• Katsuya et al. LungCancer 2015 — Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
• Hirai et al. AnticancerRes 2014 — Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma
• Strobel et al. Histopathology 2014 — Corticomedullary differentiation and maturational arrest in thymomas
• Inoue et al. JThoracOncol 2014 — Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma north japan lung cancer
• Marx et al. JThoracOncol 2014 — ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma refined
• Weksler et al. JThoracOncol 2014 — Alterations of the immune system in thymic malignancies
• Shitara et al. LungCancer 2014 — Genetic profiling of thymic carcinoma using targeted next-generation sequencing
• Syrios et al. MedOncol 2014 — Advances in thymic carcinoma diagnosis and treatment a review of literature
• Petrini et al. NatGenet 2014 — A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
• Wang et al. SciRep 2014 — Mutations of epigenetic regulatory genes are common in thymic carcinomas
• Weksler et al. AnnThoracSurg 2013 — Thymic carcinoma A multivariate analysis of factors predictive of survival in 290 patients
• Palmieri et al. CancerChemotherPharmacol 2012 — Imatinib Thymic carcinoma
• Abramyuk et al. LungCancer 2012 — Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PETCT in patients with non
• Kelly et al. JClinOncol 2011 — Thymic malignancies from clinical management to targeted therapies
• Lemma et al. JClinOncol 2011 — Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma
• Agatsuma et al. JThoracOncol 2011 — Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic
• Kaira et al. JThoracOncol 2011 — Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and beta III-tubulin in
• Otani et al. JpnJClinOncol 2011 — Burden on oncologists when communicating the discontinuation of anticancer treatment
• Okuma et al. LungCancer 2011 — Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma evaluation of efficacy and toxicity
• Kunitoh et al. BrJCancer 2010 — A phase II trial of dose-dense chemotherapy, followed by surgical resection andor thoracic radiotherapy, in locally
• Masaoka et al. JThoracOncol 2010 — Staging system of thymoma
• Kunitoh et al. BrJCancer 2009 — A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma report of a japan clinical oncology
• Girard et al. ClinCancerRes 2009 — Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas
• Huang et al. JThoracCardiovascSurg 2009 — Comparison of patterns of relapse in thymic carcinoma and thymoma
• Falkson et al. JThoracOncol 2009 — The management of thymoma a systematic review and practice guideline
• Rodewald et al. AnnuRevImmunol 2008 — Thymus organogenesis
• deJong et al. EurJCancer 2008 — Thymic epithelial tumours a population-based study of the incidence, diagnostic procedures and therapy
• Srirajaskanthan et al. LungCancer 2008 — A review of thymic tumours
• Yoh et al. LungCancer 2008 — Mutational status of EGFR and KIT in thymoma and thymic carcinoma
• Detterbeck et al. AnnThoracSurg 2006 — Clinical value of the WHO classification system of thymoma
• Duwe et al. Chest 2005 — Tumors of the mediastinum
• Sakurai et al. JpnJClinOncol 2004 — Management of primary malignant germ cell tumor of the mediastinum
• Strobel et al. NEnglJMed 2004 — Thymic carcinoma with overexpression of mutated KIT and the response to imatinib
• Kondo et al. AnnThoracSurg 2003 — Therapy for thymic epithelial tumors a clinical study of 1,320 patients from japan
• Takeda et al. Cancer 2003 — Primary germ cell tumors in the mediastinum a 50-year experience at a single japanese institution
• Engels et al. IntJCancer 2003 — Malignant thymoma in the united states demographic patterns in incidence and associations with subsequent malignancies
• Koizumi et al. AmJClinOncol 2002 — Chemotherapy for advanced thymic carcinoma clinical response to cisplatin, doxorubicin, vincristine, and
• Okumura et al. Cancer 2002 — The world health organization histologic classification system reflects the oncologic behavior of thymoma a clinical
• Rios et al. EurJCardiothoracSurg 2002 — Prognostic factors in thymic epithelial neoplasms
• Bokemeyer et al. JClinOncol 2002 — Extragonadal germ cell tumors of the mediastinum and retroperitoneum results from an international analysis
• Masaoka et al. Cancer 1981 — Follow-up study of thymomas with special reference to their clinical stages

Clinical-irAE

• Schneider et al. NatRevCancer 2026 — Microbiota and immune-related adverse events in cancer immunotherapy
• Asao et al. LungCancer 2024 — Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune
• Aung et al. ClinLungCancer 2023 — Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease A systematic
• Castelo-Branco et al. ESMOOpen 2023 — Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with
• Socinski et al. JAMAOncol 2023 — Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer
• Naidoo et al. JImmunotherCancer 2023 — SITC consensus definitions for immune checkpoint inhibitor-associated immune related adverse events (irAEs) terminology
• Panhaleux et al. EurJCancer 2022 — Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis A postmarketed
• Han et al. JAMAOncol 2022 — Association between toxic effects and survival in patients with cancer and autoimmune disease treated with checkpoint…
• Govindan et al. JImmunotherCancer 2022 — Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung
• Tison et al. NatRevRheumatol 2022 — Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
• Kostine et al. AnnRheumDis 2021 — EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer
• Sata et al. CancerSci 2021 — Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer
• Fujimoto et al. EurJCancer 2021 — Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naive patients with non-squamous non-small cell lung
• Nebhan et al. JAMAOncol 2021 — Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older
• Stock-Martineau et al. JCOOncolPract 2021 — Challenges of immunotherapy in stage IV non-small-cell lung cancer
• Brahmer et al. JImmunotherCancer 2021 — Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse
• Brown et al. JImmunotherCancer 2021 — Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
• Halle et al. JImmunotherCancer 2021 — Immune checkpoint inhibitors in patients with pre-existing psoriasis Safety and efficacy
• Zhou et al. LancetOncol 2021 — Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials a
• Michot et al. EurJCancer 2020 — The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an
• Hommes et al. FrontOncol 2020 — Biomarkers of checkpoint inhibitor induced immune-related adverse events-A comprehensive review
• Shankar et al. JAMAOncol 2020 — Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell
• Abu-Sbeih et al. JClinOncol 2020 — Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
• Bender et al. JImmunotherCancer 2020 — Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer
• Boland et al. JImmunotherCancer 2020 — Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
• Martinez et al. JImmunotherCancer 2020 — Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune
• Edfahani et al. NatRevClinOncol 2020 — Moving towards personalized treatments of immune-related adverse events
• Tison et al. ArthritisRheumatol 2019 — Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease A
• Kehl et al. CancerImmunolImmunother 2019 — Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint
• Cybulska-Stopa et al. CaseRepOncol 2019 — Immune-related pancytopenia induced by anti-PD-1 therapy-interrupt or continue treatment-the role of
• Ni et al. CaseRepOncol 2019 — AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma a case report
• Toi et al. JAMAOncol 2019 — Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer
• Suresh et al. JClinInvest 2019 — The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
• Xing et al. JImmunotherCancer 2019 — Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated
• Yoneshima et al. LungCancer 2019 — Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies
• Cortellini et al. Oncologist 2019 — Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed
• Abdel-Wahab et al. AnnInternMed 2018 — Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease
• Santini et al. CancerImmunolRes 2018 — Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC
• Danlos et al. EurJCancer 2018 — Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or
• Fujii et al. InvestNewDrugs 2018 — Incidence of immune-related adverse events and its association with treatment outcomes the MD anderson cancer center
• Haratani et al. JAMAOncol 2018 — Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer
• Leonardi et al. JClinOncol 2018 — Safety of PD-1 pathway inhibitors among patients with NSCLC and preexisting autoimmune disease
• Khan et al. LungCancer 2018 — How does autoimmune disease impact treatment and outcomes among patients with lung cancer A national SEER Medicare an…
• Tokumo et al. LungCancer 2018 — Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma
• Postow et al. NEnglJMed 2018 — Immune-related adverse events associated with immune checkpoint blockade
• Menzies et al. AnnOncol 2017 — Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with
• Giat et al. AutoimmunRev 2017 — Cancer and autoimmune diseases
• Varricchi et al. ESMOOpen 2017 — Cardiotoxicity of immune checkpoint inhibitors
• Michot et al. EurJCancer 2017 — Immune-related bone marrow failure following anti-PD1 therapy
• Coutzac et al. JCrohnsColitis 2017 — Colon immune-related adverse events anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities
• Brudno et al. Blood 2016 — Toxicities of chimeric antigen receptor T cells recognition and management
• Teachey et al. CancerDiscov 2016 — Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy
• Michot et al. EurJCancer 2016 — Immune-related adverse events with immune checkpoint blockade a comprehensive review
• Friedman et al. JAMAOncol 2016 — Treatment of the immune-related adverse effects of immune checkpoint inhibitors A review
• Johnson et al. JAMAOncol 2016 — Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
• Khan et al. JAMAOncol 2016 — Prevalence of autoimmune disease among patients with lung cancer implications for immunotherapy treatment options
• Johnson et al. NEnglJMed 2016 — Fulminant myocarditis with combination immune checkpoint blockade
• Naidoo et al. AnnOncol 2015 — Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
• Chiou et al. JClinOncol 2015 — Pseudoprogression and immune-related response in solid tumors
• Cosmai et al. JNephrol 2015 — Renal toxicity of anticancer agents targeting HER2 and EGFR
• Maus et al. CancerImmunolRes 2013 — T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
• Kochenderfer et al. Blood 2012 — B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19
• Weber et al. JClinOncol 2012 — Management of immune-related adverse events and kinetics of response with ipilimumab
• Kahler et al. JDtschDermatolGes 2011 — Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma
• Morgan et al. MolTher 2010 — Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen
• Suntharalingam et al. NEnglJMed 2006 — Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412